Wellcome Trust MRC Cambridge Stem Cell Institute

Lead Research Organisation: University of Cambridge

Abstract

Wellcome Trust MRC Cambridge Stem Cell Institute
Director: Professor Austin Smith, University of Cambridge

Stem cell science is providing a stream of new knowledge about how our bodies are made and maintained. This research brings the promise that better understanding of stem cells will lead to future medical applications. Treatments may come through several routes. First, human stem cells grown in the laboratory can be used to produce experimental models of diseased tissues and to test therapeutic drugs. Second, some disorders, including forms of cancer, involve abnormal behaviour of stem cells. As we learn how to control stem cells it may become possible to correct these faults. Third, finding how to prevent a decline in numbers and activity of stem cells may help to maintain health during ageing. Finally, stem cells could be used to renew damaged tissues and replace missing cells in certain disorders.
The Cambridge Stem Cell Institute is being formed to explore and define the properties of stem cells and establish their true medical potential. Leading research scientists, technology specialists and doctors will work side by side to create a world-leading centre of excellence in stem cell biology and medicine. The Institute will also collaborate with bioindustry and will provide high level training for young researchers from around the world.

Technical Summary

This award is to facilitate creation of a world-leading centre for fundamental and translational stem cell research at the University of Cambridge. The Cambridge Stem Cell Institute (SCI) will build upon previous Wellcome Trust and Medical Research Council funding by drawing together 30 research teams into a cohesive centre. These groups will ultimately be co-located in a purpose-designed 8000m2 facility to be constructed on the Cambridge Biomedical Research Campus. The overall objective of this proposal is to define the potential of stem cell biology for human medicine. This relies on assembling a critical mass of talent in fundamental stem cell science alongside investigators focussed on translation to medical applications. The Cambridge Stem Cell Institute will be broad-based, well-resourced and intellectually invigorating. Cross-fertilisation between pluripotent and tissue stem cell biology will stimulate basic discoveries and increase capacity to address issues of human health and disease. Based on acquiring a deep understanding of stem cells allied with a clinical perspective, Institute scientists will pioneer innovative therapeutic approaches to unmet medical needs. Platform technologies supported by a Centre grant will enable SCI to recruit and retain the most talented investigators and empower them to make ground-breaking advances in understanding stem cells and their medical applications. Fundamental research will focus at the molecular level on mechanisms of self-renewal, commitment, differentiation and reprogramming. Functional studies will address the role of stem cells in development, repair, ageing, physiology and pathologies including cancer. Disease-specific induced pluripotent stem cells will be exploited to unravel mechanisms of cellular pathogenesis and define drug targets. Strategies to mobilise endogenous stem cells for regeneration will be evaluated in animal models and in the clinic as will approaches based on cell transplantation. The Institute will provide comprehensive training in embryonic and adult stem cell biology and will seek, and offer unique opportunities for, bioindustry interaction and collaboration.
Objectives
The objectives for SCI are:
(i) to uncover fundamental principles of stem cell identity, regulation and function;
(ii) to translate this knowledge into new tools for drug discovery and diagnostics;
(iii) to pioneer therapeutic approaches based on recruitment of endogenous stem cells and/or cell transplantation strategies.

Organisations

Publications

10 25 50
 
Title Stem Cell Revolutions 
Description Austin Smith provided the voice over for the Stem Cell Revolutions film. Featuring beautiful hand-drawn animations and interviews with leading stem cell scientists, Stem Cell Revolutions charts the history and scientific evolution of stem cell research - from the earliest experiments that first revealed stem cells in the body, to leading current scientific and clinical developments 
Type Of Art Film/Video/Animation 
Year Produced 2013 
Impact Increased understanding of Stem Cell Biology on an international scale 
URL http://www.stemcellrevolutions.com/watch
 
Description Advisory board member for: Izmir Biomedicine and Genome Center, Dokuz Eylul University, Turkey
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
 
Description AstraZeneca, Stem Cell & Primary Cell Scientific Advisory Board, Sweden
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
 
Description Briefing of Policy Advisor
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description Briefing of Wellcome Trust Policy Advisor
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description Briefing of Wellcome Trust Policy Advisor - Dr Alexis Gilbert
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description CDB
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in advisory committee
 
Description Cell Fate and Cancer Programme, Centre for Genomic Regulation, Barcelona, Spain
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
 
Description Cell Therapy Catapult Academic Advisory Board, London, UK
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
 
Description Cell and Gene Therapy Catapult Scientific Advisory Board
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description CiRA Symposium, Kyoto
Geographic Reach Europe 
Policy Influence Type Influenced training of practitioners or researchers
 
Description CiRA Symposium, Kyoto
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Global COE programme, Kyoto
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in advisory committee
 
Description ISSCR - keynote speaker
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
 
Description ISSCR Advisory Board
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in advisory committee
 
Description ISSCR Board of Directors Meeting
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in advisory committee
 
Description International Scientific Advisory Board Annual Meeting 2014
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in advisory committee
 
Description MEP Briefing
Geographic Reach Europe 
Policy Influence Type Influenced training of practitioners or researchers
 
Description MEP Forum - Brussels
Geographic Reach Europe 
Policy Influence Type Participation in a national consultation
 
Description Pontifical Academy of Sciences
Geographic Reach Europe 
Policy Influence Type Participation in advisory committee
 
Description Riken Advisory Committee
Geographic Reach Asia 
Policy Influence Type Participation in a advisory committee
 
Description Riken Advisory Council
Geographic Reach Europe 
Policy Influence Type Participation in advisory committee
 
Description UKSCB Advisory Board
Geographic Reach National 
Policy Influence Type Participation in advisory committee
 
Description Wellcome Trust Sanger Institute Cellular Genetics Programme
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
 
Description Addenbrookes Charitable Trust award of Consumables for Dr. K.Kurian to work within Biochemistry: Stem Cell Institute
Amount £10,000 (GBP)
Organisation Addenbrooke's Charitable Trust (ACT) 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Advanced grant: New-Chol: Development of new therapies against Cholangiopathies (Ludovic Vallier)
Amount £2,200,000 (GBP)
Organisation European Research Council (ERC) 
Sector Public
Country European Union (EU)
Start 12/2017 
End 11/2022
 
Description BB/H012737/1 Gene Targetting by homologous recombination in the Rat
Amount £612,215 (GBP)
Funding ID BB/H012737/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 01/2011 
End 05/2015
 
Description BBSRC Stem Cell Potency
Amount £841,267 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 08/2006 
End 02/2008
 
Description Beit Memorial Fellowship for Medical Research
Amount £126,043 (GBP)
Organisation Wellcome Trust 
Department Wellcome-Beit Prize Fellowships
Sector Private
Country United Kingdom
Start 10/2007 
End 09/2010
 
Description BetaCellTherapy: Beta Cell Therapy in Diabetes
Amount £823,424 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 01/2010 
End 12/2014
 
Description Bronchiolar and Alveolar Organoids (Joo-Hyeon Lee)
Amount £153,327 (GBP)
Organisation AstraZeneca 
Department Astra Zeneca
Sector Private
Country United States
Start 12/2017 
End 12/2019
 
Description CHARACTERIZATION OF ZAP70-MEDIATED SIGNALLING PATHWAYS IN DI (Ingo Ringshausen)
Amount £218,332 (GBP)
Organisation The Kay Kendall Leukaemia Fund 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2017 
End 12/2019
 
Description Cambridge Biomedical Research Centre - funding for Cancer Molecular Diagnostic Laboratory
Amount £1,175,000 (GBP)
Organisation Cambridge University Hospitals NHS Foundation Trust 
Sector Public
Country United Kingdom
Start 04/2017 
End 03/2022
 
Description Cambridge Biomedical research Centre - funding for Cambridge Blood and Stem Cell Biobank
Amount £1,061,140 (GBP)
Organisation Cambridge University Hospitals NHS Foundation Trust 
Sector Public
Country United Kingdom
Start 04/2017 
End 03/2022
 
Description Cambridge Cancer Centre Studentship
Amount £195,918 (GBP)
Organisation Cambridge Cancer Centre 
Sector Academic/University
Country United Kingdom
Start 10/2017 
End 09/2020
 
Description Capturing formative pluripotency (Austin Smith)
Amount £662,127 (GBP)
Funding ID BB/P009867/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 04/2017 
End 03/2020
 
Description Catherine Dubrowska consumables (Lee lab)
Amount £39,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 09/2021
 
Description Centre for Stem Cell Biology & Regenerative Medicine
Amount £795,134 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2009 
End 12/2011
 
Description Characterisation of new human ES cell derived in novel
Amount £55,624 (GBP)
Funding ID 4-2005-821 
Organisation Juvenile Diabetes Research Foundation (JDRF) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2007 
End 12/2007
 
Description Collaborative bursary MiRNA expression in brain cancer stem cells
Amount £6,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Core Support for Wellcome Trust Centre for Stem Cell Research
Amount £6,956,531 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2007 
End 12/2011
 
Description Decoding the network logic for decoding pluripotency (Austin Smith)
Amount £111,786 (GBP)
Funding ID BB/P021573/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2017 
End 09/2019
 
Description Defining the prerequisites of naïve pluripotent human embryo cells for self-renewal in culture (Jenny Nichols)
Amount £683,801 (GBP)
Funding ID MR/P010423/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2017 
End 12/2019
 
Description Delimiting the stem cell phase boundary via time normalisation (Austin Smith)
Amount £224,408 (GBP)
Organisation The Leverhulme Trust 
Sector Academic/University
Country United Kingdom
Start 01/2017 
End 01/2019
 
Description Developing new models for the functional investigation of Lymphoma
Amount £104,000 (GBP)
Organisation Gilead Sciences, Inc. 
Department Gilead
Sector Private
Country United Kingdom
Start 03/2017 
End 02/2019
 
Description ESTOOLS: Platforms for Biomedical Discovery with Human ES cells
Amount £373,970 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 08/2006 
End 07/2010
 
Description EURATRANS European large-scale functional genomics in the rat for translational research (10.5m euros across 19 participants)
Amount £517,672 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 04/2010 
End 09/2014
 
Description EUROSTEMCELL: European Consortium for Stem Cell Research (0.8m euros across 11 participants)
Amount £38,175 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 09/2006 
End 01/2008
 
Description EUROSTEMCELL: European Consortium for Stem Cell Research (0.8m euros across 11 participants)
Amount £6,457 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 03/2010 
End 02/2015
 
Description EUROSYSTEM European consortium for systematic stem Cell Biology (12m euros across 24 participants)
Amount £1,184,402 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 03/2008 
End 08/2012
 
Description Embryonic Stem Cells, Neural stem cells and Neurons
Amount £102,527 (GBP)
Organisation Fidelity Biosciences 
Sector Private
Country United States
Start 05/2007 
End 05/2009
 
Description Generation of human iPSC- derived motor neurons and microglia to model ALS pathophysiology in a dish (Stefano Pluchino)
Amount £7,800 (GBP)
Organisation University of Montreal 
Department Montreal Neurological Institute
Sector Hospitals
Country Canada
Start 01/2017 
End 12/2017
 
Description HARMONY - Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in hematology
Amount £130,435 (GBP)
Organisation European Federation of Pharmaceutical Industries and Associations (EFPIA) 
Sector Private
Country Belgium
Start 01/2017 
End 12/2021
 
Description Heterogeneity of the human epicardium: molecular determinants and functional consequences (Sanjay Sinha)
Amount £185,375 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 09/2019
 
Description Horizon2020 FTE grant
Amount £2,641,920 (GBP)
Organisation European Union 
Sector Public
Country European Union (EU)
Start 11/2017 
End 12/2021
 
Description How does ageing affect remyelination potential?
Amount £257,498 (GBP)
Organisation Dr. Miriam and Sheldon G. Adelson Medical Research Foundation 
Sector Charity/Non Profit
Country United States
Start 10/2017 
End 09/2018
 
Description Impact of Cell & Gene Therapy onthe function and molecular regulation of haematopoietic stem cells (Elisa Laurenti)
Amount £136,627 (GBP)
Funding ID 1942750 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2017 
End 09/2021
 
Description Isaac Newton Trust
Amount £29,346 (GBP)
Organisation University of Cambridge 
Sector Academic/University
Country United Kingdom
Start 10/2017 
End 05/2019
 
Description Isaac Newton Trust
Amount £37,297 (GBP)
Organisation University of Cambridge 
Sector Academic/University
Country United Kingdom
Start 03/2017 
End 02/2019
 
Description Japanese Partnership
Amount £56,594 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 07/2010 
End 06/2014
 
Description Kelly Evans iCase Studentship with AstraZeneca (Lee Lab)
Amount £130,212 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2017 
End 09/2021
 
Description MRC Stem Cell Career Development Fellowship
Amount £279,872 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2008 
End 07/2011
 
Description Mathematical Genomics and Medicine Programme PhD studentship
Amount £40,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 09/2020
 
Description Mathematical clonal analysis of cancer initiating cells in homeostasis and injury-repair using modified Rosa-confetti alleles in diverse tissues
Amount £386,713 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2017 
End 01/2020
 
Description Mesenchymal contribution to early oesophagael cancer
Amount £449,996 (GBP)
Funding ID MR/P019013/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 05/2017 
End 04/2020
 
Description NeuroStemcell Project - European consortium for stem Cell therapy
Amount £652,985 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 12/2008 
End 05/2013
 
Description New therapeutic strategies for Marfan and other genetically-triggered aortic aneurysm syndromes (Sanjay Sinha)
Amount £1,281,390 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 09/2022
 
Description Ole Wiskow Studentship
Amount £22,500 (GBP)
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start 01/2007 
End 12/2009
 
Description Personalised cell-based and iron chelator therapies for hypomyelinating leukodystrophy (David Rowitch)
Amount £84,447 (GBP)
Organisation Action Medical Research 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2017 
End 11/2018
 
Description PhD Programme for Clinicians
Amount £49,500 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 10/2020
 
Description Plurimes - Pluripotent Stem Cell Resources for Mesodermal Medicine
Amount £1,511,268 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 02/2014 
End 01/2018
 
Description Precision Transgenesis in Rats via Embryonic Stem Cells
Amount £52,827 (GBP)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start 08/2006 
End 01/2009
 
Description Programme Grant
Amount £300,000 (GBP)
Organisation Bloodwise 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2017 
End 05/2020
 
Description Provision for public engagement - Stem Cell Institute Public Engagement Officer
Amount £171,011 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2014 
End 06/2017
 
Description Regulation and function of the pluripotency determinant Nanaog
Amount £844,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2006 
End 10/2010
 
Description Regulation of Self Renewal, Commitment and Differentiation in Brain Cancer Cells
Amount £177,218 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2008 
End 05/2011
 
Description Repurposing AMPAkines for enhancing myelin regeneration in Multiple Sclerosis
Amount £130,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2017 
End 07/2018
 
Description Repurposing glutamate modulators for enhancing myelin regene
Amount £70,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 02/2017 
End 10/2017
 
Description Resolving white matter disfunction in Alzheimer's disease with patient specific cell
Amount £38,373 (GBP)
Organisation University of Cambridge 
Department Isaac Newton Trust
Sector Academic/University
Country United Kingdom
Start 04/2017 
End 07/2018
 
Description Senior Cancer Research Fellowship (George Vassiliou)
Amount £1,900,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2017 
End 07/2023
 
Description Single cell isolation from heterogeneous normal and malignant cell populations
Amount £50,000 (GBP)
Organisation University of Cambridge 
Department Isaac Newton Trust
Sector Academic/University
Country United Kingdom
Start 07/2017 
End 06/2018
 
Description Statistical physics of cell fate choice
Amount £40,000 (GBP)
Organisation The Royal Society 
Sector Academic/University
Country United Kingdom
Start 12/2017 
End 11/2019
 
Description Steering Embryonic Stem Cells towards Pancreatic
Amount £43,902 (GBP)
Organisation Juvenile Diabetes Research Foundation (JDRF) 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2007 
End 04/2010
 
Description Stem Cell Initiative (Core Grant)
Amount £1,143,873 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2006 
End 12/2008
 
Description Stemstroke: Towards a Stem Cell Therapy for Stroke
Amount £294,553 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 01/2007 
End 12/2009
 
Description Studentship Ms Amanda Anderson Rolf
Amount £97,054 (GBP)
Funding ID RG70550 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2013 
End 09/2017
 
Description Summer Studentship for Magdelena Stasiulewicz
Amount £2,500 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 06/2010 
End 08/2010
 
Description Supercharging platelets to prevent blood loss after trauma and regenerate hearts after heart attack
Amount £60,000 (GBP)
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 10/2020
 
Description SyBoSS Project - Systems Biology of Stem Cells and Reprogramming
Amount £374,310 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 06/2010 
End 05/2015
 
Description Synergistic Interaction Between the Master Regulator ASCL1 and Wnt Signaling Drives Neuroblastoma (Anna Philpott)
Amount £58,920 (GBP)
Organisation The Neuroblastoma Society 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2017 
End 06/2018
 
Description The Discovery of future Neuro-therapeutic Molecules (NEUROscreen)
Amount £195,139 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 08/2007 
End 07/2010
 
Description The Road from Pluripotency to Lineage
Amount £1,736,222 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2010 
End 10/2015
 
Description The Stat3 pathway in Stem Cell Self renewal and the germline
Amount £1,211,904 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 06/2009 
End 05/2013
 
Description The impact f genomic and microenvironmental factors on phenotype myeloproliferative neoplasms
Amount £33,166 (GBP)
Organisation The Kay Kendall Leukaemia Fund 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2017 
End 01/2018
 
Description Transcriptional programmes of myeloproliferative neoplasms
Amount £1,489,605 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2017 
End 01/2022
 
Description Transplantation protocols to assess the ability of ES cell derived endodermal populations to differentiate towards pancreatic lineages
Amount £26,596 (GBP)
Organisation Juvenile Diabetes Research Foundation (JDRF) 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Understanding how the nurd complex assembles and functions in mouse embryonic stem cells
Amount £20,160 (GBP)
Funding ID MR/P019471/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 05/2017 
End 04/2022
 
Description Understanding mammalian interphase genome structure in mouse
Amount £254,618 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2017 
End 04/2022
 
Description Understanding the physical biology of adult blood stem cells
Amount £1,304,348 (GBP)
Organisation European Research Council (ERC) 
Sector Public
Country European Union (EU)
Start 05/2017 
End 04/2022
 
Description WT Research Training Fellowship: Lay Ping Ong. Does Epicardium promote Cardiomyocyte Maturation and Cardiac Regeneration? (Sanjay Sinha)
Amount £270,886 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2017 
End 12/2019
 
Description Wellcome Trust 4-Year Studentship - 5 year funding
Amount £2,512,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2016 
 
Title 'Cell Map' of early mammalian development 
Description technology to profile over 20,000 individual cells from the developing embryo to produce the first 'cell map' describing all of the major cell types present in early embryo development. The researchers used the map to identify an important new pathway involved in blood cell development and say the map could open up new avenues for medicine and drug development. 
Type Of Material Computer model/algorithm 
Year Produced 2017 
Provided To Others? Yes  
Impact The 'cell map' data also offers new drug development opportunities which could lead to future impacts.The identification of new pathways driving normal blood cell development has the potential to improve our ability to generate blood cells for these patients in the laboratory". This is a comprehensive and deep characterisation of cell types present in the mouse embryo at this critical stage of development, creating a rich resource for the community. The study illustrates the power of single cell based techniques to understand the development of organs such as the heart and brain. It could also help researchers to improve methods for creating mature, specialised cells from stem cells. 
URL https://www.nature.com/articles/s41556-017-0013-z
 
Title Computer Model to simulate blood production from stem cells 
Description CSCI and Microsoft Research developed the first computer model to simulate the growth of blood cells from stem cells. This programme will help in the development of new treatments for blood cancer. 
Type Of Material Computer model/algorithm 
Year Produced 2015 
Provided To Others? Yes  
Impact The new computer model enables researchers to carry out simulated experiments in seconds that would normally take many weeks to perform in the lab. The model will dramatically speed up research into blood development and the genetic mutations that cause leukaemia. 
URL http://www.nature.com/articles/nbt.3154
 
Description Ana Cvejic - ISB-SIB 
Organisation Swiss Institute of Bioinformatics (SIB)
Country Switzerland 
Sector Charity/Non Profit 
PI Contribution CSCI PI: Ana Cvejic; Co-author on paper.
Collaborator Contribution Collaboration with David Gfeller; Co-author on paper.
Impact Co-author on paper.
Start Year 2014
 
Description Ana Cvejic - Sanger 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution CSCI PI: Ana Cvejic; Co-author on paper.
Collaborator Contribution Collaboration with Sarah Teichmann; Co-author on paper.
Impact Co-author on paper.
Start Year 2015
 
Description Ana Cvejic - Sanger (Macaulay) 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution CSCI PI: Ana Cvejic; Co-author on paper.
Collaborator Contribution Collaboration with Ian Macaulay; Co-author on paper.
Impact Co-author on paper.
Start Year 2015
 
Description Ana Cvejic - University of Cambridge (Haematology) 
Organisation University of Cambridge
Department Cambridge Stem Cell Institute
Country United Kingdom 
Sector Multiple 
PI Contribution CSCI PI: Ana Cvejic; Co-author on paper.
Collaborator Contribution Collaboration with Willem Ouwehand; Co-author on paper.
Impact Co-author on paper.
Start Year 2012
 
Description Ana Cvejic - University of Manchester 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ana Cvejic; Co-author on paper.
Collaborator Contribution Collaboration with Adam Hurlstone; Co-author on paper.
Impact Co-author on paper.
Start Year 2016
 
Description Anna Philpott - CRUK CI 
Organisation Cancer Research UK Cambridge Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Anna Philpott; Chipseq/RNAseq analysis of transcriptional regulators of stemness/differentiation.
Collaborator Contribution Collaboration with Jason Carroll; Chipseq/RNAseq analysis of transcriptional regulators of stemness/differentiation.
Impact Chipseq/RNAseq analysis of transcriptional regulators of stemness/differentiation.
Start Year 2012
 
Description Anna Philpott - Gurdon 
Organisation University of Cambridge
Department Gurdon Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Anna Philpott;; Transcriptional dynamics.
Collaborator Contribution Collaboration with John Gurdon; Transcriptional dynamics.
Impact Transcriptional dynamics.
Start Year 2011
 
Description Anna Philpott - Harvard Medical School 
Organisation Harvard University
Department Harvard Medical School
Country United States 
Sector Academic/University 
PI Contribution CSCI PI: Anna Philpott; Mathematical modelling of transcriptional dynamics.
Collaborator Contribution Collaboration with Jeremy Gunawardena; Mathematical modelling of transcriptional dynamics.
Impact Mathematical modelling of transcriptional dynamics.
Start Year 2010
 
Description Anna Philpott - Harvard Stem Cell Institute 
Organisation Harvard University
Department Harvard Stem Cell Institute
Country United States 
Sector Academic/University 
PI Contribution CSCI PI: Anna Philpott; Collaborator on an MRC grant on islet cell formation in the pancreas.
Collaborator Contribution Collaboration with Doug Melton.; Collaborator on an MRC grant on islet cell formation in the pancreas.
Impact Collaborator on an MRC grant on islet cell formation in the pancreas.
Start Year 2013
 
Description Austin Smith - AstraZeneca 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI: Austin Smith; Advisory Board.
Collaborator Contribution Collaboration with Lorenz Mayr; Advisory Board.
Impact Advisory Board.
Start Year 2015
 
Description Austin Smith - Cell Therapy Catapult 
Organisation Cell Therapy Catapult
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Austin Smith; Advisory Board.
Collaborator Contribution Collaboration with Johan Hyllner; Adviosry Board.
Impact Advisory Board.
Start Year 2014
 
Description Austin Smith - Microsoft Research 
Organisation Microsoft Research
Country Global 
Sector Private 
PI Contribution CSCI PI: Austin Smith; Computational Modelling.
Collaborator Contribution Collaboration with Stephen Emmott and Sara-Jane Dunn; Computational modelling.
Impact Computational modelling; Joint publications.
Start Year 2013
 
Description Austin Smith - PSCP 
Organisation Loughborough University
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Austin Smith; The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies.
Collaborator Contribution The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies.
Impact The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies.
Start Year 2013
 
Description Austin Smith - PSCP 
Organisation University of Sheffield
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Austin Smith; The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies.
Collaborator Contribution The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies.
Impact The PSCP aims to lay foundations for a generic translational pipeline from the derivation of clinical grade pluripotent stem cells to potential cell therapies.
Start Year 2013
 
Description Austin Smith - StemCell Technologies 
Organisation Stemcell Technologies
Country Canada 
Sector Private 
PI Contribution CSCI PI: Austin Smith; Partner in EC project plus licensing agreement.
Collaborator Contribution Collaboration with Sharon Louis and Allen Eaves; Partner in EC project plus licensing agreement.
Impact Partner in EC project plus licensing agreement.
Start Year 2014
 
Description BK Koo - Sanger 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution CSCI PI: Bon-Kyoung Koo; We will look into single cell transcriptomics of Troy+ stomach stem cells. Sanger will use the funds under this RRC to carry out single cell sorting and RCA sequencing of 10 stomach stem cell samples provided by Cambridge, and both parties will collaborate on the analysis of the data.
Collaborator Contribution Collaboration with John Marioni; We will look into single cell transcriptomics of Troy+ stomach stem cells. Sanger will use the funds under this RRC to carry out single cell sorting and RCA sequencing of 10 stomach stem cell samples provided by Cambridge, and both parties will collaborate on the analysis of the data.
Impact We will look into single cell transcriptomics of Troy+ stomach stem cells. Sanger will use the funds under this RRC to carry out single cell sorting and RCA sequencing of 10 stomach stem cell samples provided by Cambridge, and both parties will collaborate on the analysis of the data.
Start Year 2016
 
Description BK Koo - University Carl Gustav Carus 
Organisation University Hospital Carl Gustav Carus Dresden
Country Germany 
Sector Academic/University 
PI Contribution CSCI PI: Bon-Kyoung Koo; ERC Starting Grant.
Collaborator Contribution Collaboration with Daniel Stange.
Impact Joint meeting for developing placenta and endometrium organoids.
Start Year 2014
 
Description BK Koo - University of Cambridge (Centre for Trophoblast Research) 
Organisation University of Cambridge
Department Department of Haematology
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Bon-Kyoung Koo; Joint meeting for developing placenta and endometrium organoids.
Collaborator Contribution Collaboration with Graham Burton and Ashley Moffett; Joint meeting for developing placenta and endometrium organoids.
Impact Joint meeting for developing placenta and endometrium organoids.
Start Year 2014
 
Description Ben Simons - Danstem 
Organisation University of Copenhagen
Department Psychiatric Center Copenhagen
Country Denmark 
Sector Academic/University 
PI Contribution CSCI PI: Ben Simons; Development of the mouse intestinal epithelium and development of epidermal appendages.
Collaborator Contribution Collaboration with Kim Jensen; Development of the mouse intestinal epithelium and development of epidermal appendages.
Impact Development of the mouse intestinal epithelium and development of epidermal appendages.
Start Year 2016
 
Description Ben Simons - Hospital for Sick Children 
Organisation Hospital for Sick Children, Toronto
Country Canada 
Sector Hospitals 
PI Contribution CSCI PI: Ben Simons; Dynamics of tumour propagating cells in medullablastoma and gioblastoma.
Collaborator Contribution Collaboration with Peter Dirks; Dynamics of tumour propagating cells in medullablastoma and gioblastoma.
Impact Dynamics of tumour propagating cells in medullablastoma and gioblastoma.
Start Year 2013
 
Description Ben Simons - Hubrecht Institute 
Organisation Royal Netherlands Academy of Arts and Sciences
Department Hubrecht Institute
Country Netherlands 
Sector Academic/University 
PI Contribution CSCI PI: Ben Simons; Maintenance of the adult subventricular zone.
Collaborator Contribution Collaboration with Hans Clevers; Maintenance of the adult subventricular zone.
Impact Maintenance of the adult subventricular zone.
Start Year 2010
 
Description Ben Simons - Hubrecht Institute 
Organisation Royal Netherlands Academy of Arts and Sciences
Department Hubrecht Institute
Country Netherlands 
Sector Academic/University 
PI Contribution CSCI PI: Ben Simons; Maintenance of the intestinal epithelium and development of the mammary epithelium.
Collaborator Contribution Collaboration with Jacco van Rheenen; Maintenance of the intestinal epithelium and development of the mammary epithelium.
Impact Maintenance of the intestinal epithelium and development of the mammary epithelium.
Start Year 2013
 
Description Ben Simons - John Hopkins Medical School 
Organisation Johns Hopkins University
Department School of Medicine Johns Hopkins
Country United States 
Sector Academic/University 
PI Contribution CSCI PI: Ben Simons; Maintenance of the adult subgranular zone.
Collaborator Contribution Collaboration with Hongjun Song; Maintenance of the adult subgranular zone.
Impact Maintenance of the adult subgranular zone.
Start Year 2012
 
Description Ben Simons - Memorial Sloane Kettering Cancer Center 
Organisation Memorial Sloan Kettering Cancer Center
Country United States 
Sector Academic/University 
PI Contribution CSCI PI: Ben Simons; Development of mouse neocortex.
Collaborator Contribution Collaboration with Songhai Shi; Development of mouse neocortex.
Impact Development of mouse neocortex.
Start Year 2013
 
Description Ben Simons - National Institute for Basic Biology 
Organisation Ministry of the Environment
Department National Institute for Basic Biology (NIBB)
Country Japan 
Sector Public 
PI Contribution CSCI PI: Ben Simons; Spermatogenesis in mouse.
Collaborator Contribution Collaboration with Shosei Yoshida; Spermatogenesis in mouse.
Impact Spermatogenesis in mouse.
Start Year 2009
 
Description Ben Simons - Universite Libre de Bruxelles 
Organisation University Libre Bruxelles (Université Libre de Bruxelles ULB)
Country Belgium 
Sector Academic/University 
PI Contribution CSCI PI: Ben Simons; Mechanisms of development and tumour initiation in epidermis.
Collaborator Contribution Collaboration with Cedric Blanpain; Mechanisms of development and tumour initiation in epidermis.
Impact Mechanisms of development and tumour initiation in epidermis. Several publications.
Start Year 2011
 
Description Ben Simons - University College London 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ben Simons; Maintenance of human airways.
Collaborator Contribution Collaboration with Samuel Janes; Maintenance of human airways.
Impact Maintenance of human airways.
Start Year 2012
 
Description Ben Simons - University of Cambridge (PDN) 
Organisation University of Cambridge
Department Department of Psychology
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ben Simons; Development of zebrafish retina.
Collaborator Contribution Collaboration with William Harris; Development of zebrafish retina.
Impact Development of zebrafish retina.
Start Year 2011
 
Description Bertie Gottgens - Autolus 
Organisation Autolus Limited
Department Autolus
Country Poland 
Sector Private 
PI Contribution CSCI PI: Bertie Gottgens; Single cell genomics analysis of CAR-T cells.
Collaborator Contribution Collaboration with Nina Kotsopoulou; Single cell genomics analysis of CAR-T cells.
Impact Single cell genomics analysis of CAR-T cells.
Start Year 2016
 
Description Bertie Gottgens - Baylor College of Medicine 
Organisation Baylor College of Medicine
Country United States 
Sector Hospitals 
PI Contribution CSCI PI: Bertie Gottgens; Joint research papers.
Collaborator Contribution Collaboration with Peggy Goodell; Joint research papers.
Impact Joint research papers.
Start Year 2014
 
Description Bertie Gottgens - Centro de Medicina Regenerativa de Barcelona 
Organisation Center of Regenerative Medicine in Barcelona
Country Spain 
Sector Hospitals 
PI Contribution CSCI PI: Bertie Gottgens; RNA-Seq.
Collaborator Contribution Collaboration with Alessandra Giorgetti; RNA-seq
Impact RNA-seq.
Start Year 2016
 
Description Bertie Gottgens - David Bryder 
Organisation Lund University
Country Sweden 
Sector Academic/University 
PI Contribution CSCI PI: Bertie Gottgens - Joint research paper.
Collaborator Contribution Collaboration with David Bryder - Joint research paper.
Impact Joint research paper.
Start Year 2017
 
Description Bertie Gottgens - Dresden 
Organisation Technical University of Dresden
Country Germany 
Sector Academic/University 
PI Contribution CSCI PI: Bertie Gottgens.
Collaborator Contribution Collaboration with Claudia Waskow.
Impact None yet.
Start Year 2016
 
Description Bertie Gottgens - EBI 
Organisation EMBL European Bioinformatics Institute (EMBL - EBI)
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Bertie Gottgens; Joint research papers.
Collaborator Contribution Collaboration with John Marioni; Joint research papers.
Impact Joint research papers.
Start Year 2015
 
Description Bertie Gottgens - Fiona Gribble 
Organisation University of Cambridge
Department Department of Clinical Biochemistry
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Bertie Gottgens - Joint research paper.
Collaborator Contribution Collaboration with Fiona Gribble - joint research paper.
Impact Joint research paper.
Start Year 2017
 
Description Bertie Gottgens - GSK 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution CSCI PI: Bertie Gottgens; Single cell profiling of gene therapy products.
Collaborator Contribution Single cell profiling of gene therapy products.
Impact Single cell profiling of gene therapy products.
Start Year 2016
 
Description Bertie Gottgens - Ross Hardison 
Organisation Penn State University
Country United States 
Sector Academic/University 
PI Contribution CSCI PI: Bertie Gottgens; Joint National Institutes of Health grant
Collaborator Contribution Collaboration with Ross Hardison - Joint National Institutes of Health grant.
Impact Joint National Institutes of Health grant
Start Year 2017
 
Description Bertie Gottgens - Sheba Medical Centre 
Organisation Sheba Medical Centre
Country Israel 
Sector Hospitals 
PI Contribution CSCI PI: Bertie Gottgens; Joint research papers.
Collaborator Contribution Collaboration with Shai Izraeli; Joint research papers.
Impact Joint research papers.
 
Description Bertie Gottgens - Thomas Mercher 
Organisation Gustave-Roussy Institute
Country France 
Sector Multiple 
PI Contribution CSCI PI: Bertie Gottgens - Single cell analysis
Collaborator Contribution Collaboration with Thomas Mercher - Single cell analysis
Impact Single cell analysis.
Start Year 2017
 
Description Bertie Gottgens - Universidad Pablo de Olavide 
Organisation Pablo de Olavide University
Country Spain 
Sector Academic/University 
PI Contribution CSCI PI: Bertie Gottgens; Joint research papers.
Collaborator Contribution Collaboration with Maria Jose Sanchez; Joint research papers.
Impact Joint research papers.
Start Year 2016
 
Description Bertie Gottgens - University of Birmigham 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution Joint research papers. Joint BBSRC LoLa Award.
Collaborator Contribution Collaboration with Constanze Bonifer, Georges Lacaud and Valeirie Kouskoff; Joint research papers. Joint BBSRC LoLa Award
Impact Joint research papers. Joint BBSRC LoLa Award.
Start Year 2011
 
Description Bertie Gottgens - University of Birmigham 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution Joint research papers. Joint BBSRC LoLa Award.
Collaborator Contribution Collaboration with Constanze Bonifer, Georges Lacaud and Valeirie Kouskoff; Joint research papers. Joint BBSRC LoLa Award
Impact Joint research papers. Joint BBSRC LoLa Award.
Start Year 2011
 
Description Bertie Gottgens - University of California San Francisco 
Organisation University of California, San Francisco
Country United States 
Sector Academic/University 
PI Contribution CSCI PI: Bertie Gottgens; Joint publication.
Collaborator Contribution Collaboration with Emanuelle Passegue; Joint publication.
Impact Joint publication.
Start Year 2016
 
Description Bertie Gottgens - University of Cambridge (Genetics) 
Organisation University of Cambridge
Department Department of Biochemistry
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Bertie Gottgens; Joint research papers.
Collaborator Contribution Collaboration with Boris Adryan; Joint research papers.
Impact Joint research papers.
Start Year 2015
 
Description Bertie Gottgens - University of New South Wales 
Organisation University of New South Wales
Country Australia 
Sector Academic/University 
PI Contribution CSCI PI: Bertie Gottgens; Joint research papers.
Collaborator Contribution Collaborations with John Pimanda; Joint research papers.
Impact Joint research papers.
Start Year 2007
 
Description Bertie Gottgens - University of Oxford 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Bertie Gottgens; Single cell analysis.
Collaborator Contribution Collaboration with John Todd; Single cell analysis.
Impact Single cell analysis. None yet.
Start Year 2016
 
Description Bertie Gottgens - Vrifje University of Amsterdam 
Organisation Free University of Amsterdam
Country Netherlands 
Sector Academic/University 
PI Contribution CSCI PI: Bertie Gottgens; Joint research papers.
Collaborator Contribution Collaboration with Nicola Bonzanni; Joint research papers
Impact Joint research papers.
Start Year 2008
 
Description Bertie Gottgens - WIMM 
Organisation University of Oxford
Department Weatherall Institute of Molecular Medicine (WIMM)
Country United Kingdom 
Sector Public 
PI Contribution CSCI PI: Bertie Gottgens; Joint research papers.
Collaborator Contribution Collaboration with Marella de Brujin; Joint research papers.
Impact Joint research papers.
Start Year 2007
 
Description Beta Cell Therapy / SCI 
Organisation JDRF Center for Beta Cell Therapy in Diabetes
Country Belgium 
Sector Academic/University 
PI Contribution Beta Cell Therapy in Diabetes - European Framework 7
Collaborator Contribution Beta Cell Therapy in Diabetes - European Framework 7
Impact n/a
Start Year 2010
 
Description Brian Hendrich - EMBL 
Organisation European Molecular Biology Laboratory
Department EMBL-Grenoble
Country France 
Sector Academic/University 
PI Contribution CSCI PI: Brian Hendrich; Collaboration on NuRD structure. Co-PI on EU FP7 Grant.
Collaborator Contribution Collaboration with Imre Berger; Collaboration on NuRD structure. Co-PI on EU FP7 Grant.
Impact Collaboration on NuRD structure. Co-PI on EU FP7 Grant.
Start Year 2013
 
Description Brian Hendrich - European Institute of Oncology 
Organisation European Institute of Oncology (IEO)
Country Italy 
Sector Charity/Non Profit 
PI Contribution CSCI PI: Brian Hendrich; Collaborative small molecule screens. Co-PI on EU FP7 grant.
Collaborator Contribution Collaboration with Saverio Minucci; Collaborative small molecule screens. Co-PI on EU FP7 grant.
Impact Collaborative small molecule screens. Co-PI on EU FP7 grant.
Start Year 2012
 
Description Brian Hendrich - MRC CSC 
Organisation Medical Research Council (MRC)
Department MRC Clinical Sciences Centre (CSC)
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Brian Hendrich; Joint authored paper submitted.
Collaborator Contribution Collaboration with Matthias Merkenschlager; Joint authored paper submitted.
Impact Joint authored paper submitted.
Start Year 2015
 
Description Brian Hendrich - Sandra Hake 
Organisation Justus Liebig University Giessen
Country Germany 
Sector Academic/University 
PI Contribution CSCI PI: Brian Hendrich - Investigation of Mta protein function: one joint publication in preparation
Collaborator Contribution Collaboration with Sandra Hake - Investigation of Mta protein function: one joint publication in preparation
Impact Investigation of Mta protein function: one joint publication in preparation.
Start Year 2016
 
Description Brian Hendrich - Trinity College Dublin 
Organisation Trinity College Dublin
Country Ireland 
Sector Academic/University 
PI Contribution CSCI PI: Brian Hendrich; Function of chromatin remodellers in development and cancer. Joint grant application planned.
Collaborator Contribution Collaboration with Adrian Bracken; Function of chromatin remodellers in development and cancer. Joint grant application planned.
Impact Function of chromatin remodellers in development and cancer. Joint grant application planned.
Start Year 2015
 
Description Brian Hendrich - University Medical Centre Utrecht 
Organisation University Medical Center Utrecht (UMC)
Country Netherlands 
Sector Academic/University 
PI Contribution CSCI PI: Brian Hendrich; Collaborative investigation into protein complex structure. Co-PI on EU FP7 Grant, one joint paper published.
Collaborator Contribution Collaboration with Michiel Vermeulen; Collaborative investigation into protein complex structure. Co-PI on EU FP7 Grant, one joint paper published.
Impact Collaborative investigation into protein complex structure. Co-PI on EU FP7 Grant, one joint paper published
Start Year 2013
 
Description Brian Hendrich - University of Cambridge (Biochemistry - Lilley) 
Organisation University of Cambridge
Department Department of Chemistry
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Brian Hendrich; Collaborative research, named on her grant applications.
Collaborator Contribution Collaboration with Kathryn Lilley; Collaborative research, named on her grant applications.
Impact Collaborative research, named on her grant applications.
Start Year 2014
 
Description Brian Hendrich - University of Cambridge (Biochemistry) 
Organisation University of Cambridge
Department Department of Biochemistry
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Brian Hendrich; One EU FP7 grant awarded to us both, I am named collaborator on one grant and other applications. Ongoing technology development , one joint paper published.
Collaborator Contribution Collaboration with Ernest Laue; One EU FP7 grant awarded to us both, I am named collaborator on one grant and other applications. Ongoing technology development , one joint paper published.
Impact One EU FP7 grant awarded to us both, I am named collaborator on one grant and other applications. Ongoing technology development , one joint paper published.
Start Year 2009
 
Description Brian Hendrich - University of Edinburgh 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Brian Hendrich; Joint research efforts, one joint group meeting in Edinburgh, discussing grant options.
Collaborator Contribution Collaboration with Adrian Bird; Joint research efforts, one joint group meeting in Edinburgh, discussing grant options.
Impact Joint research efforts, one joint group meeting in Edinburgh, discussing grant options.
Start Year 2014
 
Description Brian Hendrich - University of Kumamoto 
Organisation University of Kumamoto
Country Japan 
Sector Academic/University 
PI Contribution CSCI PI: Brian Hendrich; Mice supplied, one joint paper published.
Collaborator Contribution Collaboration with Ryuichi Nishinakamura; Mice supplied, one joint paper published.
Impact Mice supplied, one joint paper published.
Start Year 2012
 
Description Brian Hendrich - University of Sussex 
Organisation University of Sussex
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Brian Hendrich; Investigating DNA repair function of CHD4.
Collaborator Contribution Collaboration with Jessica Downs; Investigating DNA repair function of CHD4.
Impact Investigating DNA repair function of CHD4.
Start Year 2014
 
Description Brian Huntly - David Adams 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution CSCI PI: Brian Huntly - Joint papers
Collaborator Contribution Collaboration with David Adams - joint papers.
Impact Joint papers.
Start Year 2017
 
Description Brian Huntly - Denis Calado, Jude Fitzgibbon, Jessica Okusun 
Organisation Francis Crick Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution CSCI PI: Brian Huntly - academic collaboration
Collaborator Contribution Collaboration with Denis Calado, Jude Fitzgibbon, Jessica Okusun.
Impact Academic collaboration - ongoing.
Start Year 2017
 
Description Brian Huntly - GSK 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution CSCI PI: Brian Huntly; Mechanistic, pre-clinical investigation of BET inhibitors.
Collaborator Contribution Collaboration with Rab Prinjha; Mechanistic, pre-clinical investigation of BET inhibitors.
Impact Mechanistic, pre-clinical investigation of BET inhibitors.
Start Year 2013
 
Description Brian Huntly - GSK Cancer Epigenetics DPU 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution CSCI PI: Brian Huntly; Translational collaboration re experimental therapeutics.
Collaborator Contribution Collaboration with Peter Tumino; Translational collaboration re experimental therapeutics.
Impact Translational collaboration re experimental therapeutics.
Start Year 2012
 
Description Brian Huntly - John Pimanda 
Organisation University of New South Wales
Country Australia 
Sector Academic/University 
PI Contribution CSCI PI: Brian Huntly - Joint papers.
Collaborator Contribution Collaboration with John Pimanda - joint papers.
Impact Joint papers.
Start Year 2015
 
Description Brian Huntly - Kings College London 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Brian Huntly; Academic collaboration.
Collaborator Contribution Collaboration with Cameron Osbourne; Academic collaboration.
Impact Academic collaboration.
Start Year 2014
 
Description Brian Huntly - MRC Cancer Unit 
Organisation University of Cambridge
Department MRC Cancer Unit
Country United Kingdom 
Sector Public 
PI Contribution CSCI PI: Brian Huntly; Academic collaboration.
Collaborator Contribution Collaboration with Christian Frezza; Academic collaboration.
Impact Academic collaboration.
Start Year 2012
 
Description Brian Huntly - Ming Du 
Organisation University of Cambridge
Department Department of Pathology
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Brian Huntly - Joint papers
Collaborator Contribution Collaboration with Ming-Qing Du - joint papers.
Impact Joint papers.
Start Year 2017
 
Description Brian Huntly - Nigel Brooks 
Organisation CellCentric Ltd
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI: Brian Huntly - Investigation of CREBBP/p300 inhibitor.
Collaborator Contribution Collaboration with Nigel Brooks - Investigation of CREBBP/p300 inhibitor.
Impact Investigation of CREBBP/p300 inhibitor.
Start Year 2017
 
Description Brian Huntly - Pfizer 
Organisation Pfizer Ltd
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI: Brian Huntly; Translational collaboration re experimental therapeutics.
Collaborator Contribution Collaboration with Kevin Lee; Translational collaboration re experimental therapeutics.
Impact Translational collaboration re experimental therapeutics.
Start Year 2012
 
Description Brian Huntly - Radek Skoda 
Organisation University of Basel
Department University Hospital Basel
Country Switzerland 
Sector Hospitals 
PI Contribution CSCI PI: Brian Huntly - Academic collaboration
Collaborator Contribution Collaboration with Radek Skoda - academic collaboration.
Impact Academic collaboration.
Start Year 2017
 
Description Brian Huntly - Ulrich Steidl 
Organisation Albert Einstein College of Medicine
Country United States 
Sector Academic/University 
PI Contribution CSCI PI: Brian Huntly - academic collaboration.
Collaborator Contribution Collaboration with Ulrich Steidl - academic collaboration.
Impact Academic collaboration.
Start Year 2017
 
Description Brian Huntly - University of Cambridge (Gurdon) 
Organisation National Institute for Health Research
Department NIHR Cambridge Biomedical Research Centre
Country United Kingdom 
Sector Public 
PI Contribution CSCI PI: Brian Huntly; Academic collaboration.
Collaborator Contribution Collaboration with Tony Kouzarides.
Impact Academic collaboration.
Start Year 2010
 
Description Brian Huntly - University of Copenhagen 
Organisation University of Copenhagen
Department Department of Veterinary Disease Biology
Country Denmark 
Sector Academic/University 
PI Contribution CSCI PI: Brian Huntly; Generation of acetylation target datasets.
Collaborator Contribution Collaboration with Chuna Ram Choudhary; Generation of acetylation target datasets.
Impact Generation of acetylation target datasets.
Start Year 2013
 
Description Brian Huntly - University of Edinburgh 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Brian Huntly; Academic collaboration.
Collaborator Contribution Collaboration with KAtrin Ottersbach; Academic collaboration.
Impact Joint paper; Academic collaboration.
Start Year 2008
 
Description Cedric Ghevaert - DefiniGEN 
Organisation DefiniGEN
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI: Cedric Ghevaert; Discussions around licence for megakaryocyte patent.
Collaborator Contribution Collaboration with Marcus Yeo; Discussions around licence for megakaryocyte patent.
Impact Discussions around licence for megakaryocyte patent.
Start Year 2016
 
Description Cedric Ghevaert - Platelet Biogenesis 
Organisation University of Hawaii
Department Institute for Biogenesis Research
Country United States 
Sector Academic/University 
PI Contribution CSCI PI: Cedric Ghevaert; Discussions around licence for megakaryocyte patent.
Collaborator Contribution Collaboration with Jonathon Thon; Discussions around licence for megakaryocyte patent.
Impact Discussions around licence for megakaryocyte patent.
Start Year 2016
 
Description Cedric Ghevaert - Platod 
Organisation PLATOD
Country France 
Sector Private 
PI Contribution CSCI PI: Cedric Ghevaert. Discussions around licence for megakaryocyte patent.
Collaborator Contribution Collaboration with Dominic Baruch; Discussions around licence for megakaryocyte patent.
Impact Discussions around licence for megakaryocyte patent.
Start Year 2016
 
Description Cedric Ghevaert - Ruth Cameron and Serena Best 
Organisation University of Cambridge
Department Department of Materials Science & Metallurgy
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Cedric Ghevaert; Bioscaffold
Collaborator Contribution Collaboration with Ruth Cameron and Serena Best - bioscaffold
Impact Bioscaffold
Start Year 2014
 
Description Computational Modelling 
Organisation Microsoft Research
Department Microsoft Research Cambridge
Country United Kingdom 
Sector Private 
PI Contribution Computational Modelling
Collaborator Contribution Computational Modelling
Impact n/a
Start Year 2010
 
Description Dan Hodson - Babraham 
Organisation Babraham Institute
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI: Dan Hodson; Collaborative research.
Collaborator Contribution Collaboration with David Turner; Collaborative research.
Impact None yet
Start Year 2013
 
Description David Kent - EBI 
Organisation EMBL European Bioinformatics Institute (EMBL - EBI)
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: David Kent; Machine Learning and quantitative biology.
Collaborator Contribution Collaboration with Florian Buttner;Machine Learning and quantitative biology.
Impact Machine Learning and quantitative biology.
Start Year 2015
 
Description David Kent - GSK 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution CSCI PI: David Kent; GSK / BBSRC CASE Studentship (M Shepherd) - quantitative and systems biology.
Collaborator Contribution Collaboration with Armin Sepp; GSK / BBSRC CASE Studentship (M Shepherd) - quantitative and systems biology.
Impact GSK / BBSRC CASE Studentship (M Shepherd) - quantitative and systems biology.
Start Year 2016
 
Description David Kent - Memorial Sloan Kettering 
Organisation Memorial Sloan Kettering Cancer Center
Country United States 
Sector Academic/University 
PI Contribution CSCI PI: David Kent; Sequencing and clinical genomics.
Collaborator Contribution Collaboration with Elli Papaemmanuil; Sequencing and clinical genomics.
Impact Sequencing and clinical genomics.
Start Year 2013
 
Description David Kent - University of British Columbia 
Organisation University of British Columbia
Country Canada 
Sector Academic/University 
PI Contribution CSCI PI: David Kent; Reagents and knowledge transfer.
Collaborator Contribution Collaboration with Connie Eaves; Reagents and knowledge transfer.
Impact Reagents and knowledge transfer.
 
Description David Kent - Weizmann Institute 
Organisation Weizmann Institute of Science
Country Israel 
Sector Academic/University 
PI Contribution CSCI PI: David Kent; Asymmetric Division of HSCs.
Collaborator Contribution Collaborationwith Tsvee Lapidot; Asymmetric Division of HSCs.
Impact Asymmetric Division of HSCs.
Start Year 2015
 
Description David Rowitch - StemCells Inc 
Organisation StemCells, Inc.
Country United States 
Sector Private 
PI Contribution CSCI PI: David Rowitch; Collaborative research.
Collaborator Contribution Collaborative research.
Impact Collaborative research.
Start Year 2010
 
Description Deep Sequencing 
Organisation Radboud University Nijmegen Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution Deep Sequencing
Collaborator Contribution Deep Sequencing
Impact n/a
Start Year 2011
 
Description EBI / SCI 
Organisation EMBL European Bioinformatics Institute (EMBL - EBI)
Country United Kingdom 
Sector Academic/University 
PI Contribution Deep sequence analysis
Collaborator Contribution Deep sequence analysis
Impact Publication: Identification of the missing pluripotency mediator downstream of leukaemia inhibitory
Start Year 2011
 
Description ESTOOLS 
Organisation Academy of Sciences of the Czech Republic
Country Czech Republic 
Sector Learned Society 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation Babraham Institute
Department Stem Cell Sciences UK Ltd
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation Bellvitge Biomedical Research Institute
Country Spain 
Sector Charity/Non Profit 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation Hebrew University of Jerusalem
Country Israel 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation Lund University
Country Sweden 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation Netherlands Cancer Institute (NKI)
Country Netherlands 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation Stem Cell Technologies
Country Canada 
Sector Private 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation Tampere University of Technology
Country Finland 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation Technical University of Dresden
Country Germany 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation University of Basel
Country Switzerland 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation University of Bonn
Department Medical Centre Bonn
Country Germany 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation University of Helsinki
Country Finland 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation University of Milan
Country Italy 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation University of Sheffield
Country United Kingdom 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description ESTOOLS 
Organisation University of Turku
Country Finland 
Sector Academic/University 
PI Contribution PI
Collaborator Contribution 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI
Impact Not Given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation Babraham Institute
Department Stem Cell Sciences UK Ltd
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation Cancer Research UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation European Molecular Biology Laboratory
Country Germany 
Sector Public 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation Lund University
Country Sweden 
Sector Academic/University 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation NeuroNova AB
Country Sweden 
Sector Private 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation NsGene A/S
Country Denmark 
Sector Private 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation Pasteur Institute, Paris
Country France 
Sector Academic/University 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation San Raffaele Hospital
Department Stem Cell Research Institute
Country Italy 
Sector Hospitals 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation Swiss Federal Institute of Technology in Lausanne (EPFL)
Country Switzerland 
Sector Public 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation University of Bonn
Department Medical Centre Bonn
Country Germany 
Sector Academic/University 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description EUROSTEMCELL 
Organisation University of Milan
Country Italy 
Sector Academic/University 
PI Contribution Austin Smith was the coordinator of this collaboration.
Collaborator Contribution xxx
Impact Not given
Start Year 2006
 
Description Elisa Laurenti - EPFL 
Organisation Swiss Federal Institute of Technology in Lausanne (EPFL)
Country Switzerland 
Sector Public 
PI Contribution CSCI PI: Elisa Laurenti; Joint publications.
Collaborator Contribution Collaboration with Didier Trono; Joint publications.
Impact Joint publications.
Start Year 2007
 
Description Elisa Laurenti - Hitoshi Takizawa 
Organisation Kumamoto University
PI Contribution CSCI PI: Elisa Laurenti - Studying adult human haematopoietic stem cells using a humanised bone marrow environment.
Collaborator Contribution Collaboration with Hitoshi Takizawa - Studying adult human haematopoietic stem cells using a humanised bone marrow environment.
Impact Studying adult human haematopoietic stem cells using a humanised bone marrow environment.
Start Year 2017
 
Description Elisa Laurenti - Liran Shlush 
Organisation Weizmann Institute of Science
Country Israel 
Sector Academic/University 
PI Contribution CSCI PI: Elisa Laurenti - Functional effects of preleukaemic mutations on human haematopoietic stem cells.
Collaborator Contribution Collaboration with Liran Shlush - Functional effects of preleukaemic mutations on human haematopoietic stem cells.
Impact Functional effects of preleukaemic mutations on human haematopoietic stem cells.
Start Year 2017
 
Description Elisa Laurenti - Universite Paris Descartes 
Organisation University of Paris - Descartes
Country France 
Sector Academic/University 
PI Contribution CSCI PI: Elisa Laurenti; The transcriptional programmes of T-Acute Lymphoblastic Leukaemia.
Collaborator Contribution Collaboration with Elizabeth Macintyre; The transcriptional programmes of T-Acute Lymphoblastic Leukaemia.
Impact The transcriptional programmes of T-Acute Lymphoblastic Leukaemia.
Start Year 2015
 
Description Elisa Laurenti - University Health Network 
Organisation University Health Network (UHN)
Country Canada 
Sector Academic/University 
PI Contribution CSCI PI: Elisa Laurenti; Joint publications.
Collaborator Contribution Collaboration with John Dick; Joint publications.
Impact Joint publications.
Start Year 2014
 
Description Elisa Laurenti - University of Cambridge (Haematology) 
Organisation UK Clinical Research Collaboration
Department Centre for Diet and Activity Research (CEDAR)
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Elisa Laurenti; Effects of inflammation on HSC; study of adult human HSC.
Collaborator Contribution Collaboration with Willem Ouwehand and Mattia Frontini; Effects of inflammation on HSC; study of adult human HSC.
Impact Effects of inflammation on HSC; study of adult human HSC.
Start Year 2014
 
Description Elisa Laurenti - University of Cambridge (Surgery) 
Organisation University of Cambridge
Department Department of Engineering
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Elisa Laurenti; Study of adult human HSC and their cryopreservation.
Collaborator Contribution Collaboration with Kouroush Saeb-Parsy.; Study of adult human HSC and their cryopreservation.
Impact Study of adult human HSC and their cryopreservation.
Start Year 2015
 
Description Euratrans 
Organisation Academy of Sciences of the Czech Republic
Country Czech Republic 
Sector Learned Society 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation Alternative Energies and Atomic Energy Commission (CEA)
Country France 
Sector Public 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation European Molecular Biology Laboratory
Country Germany 
Sector Public 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation Helmholtz Association of German Research Centres
Department The Max Delbrück Center for Molecular Medicine (MDC)
Country Germany 
Sector Academic/University 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation Max Planck Society
Department Max Planck Institute of Biochemistry
Country Germany 
Sector Public 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation Medical College of Wisconsin
Country United States 
Sector Academic/University 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation National Institute of Health and Medical Research (INSERM)
Country France 
Sector Public 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation Research Network Services (RNSL) Ltd Berlin
Country Germany 
Sector Private 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation Royal Institute of Technology
Country Sweden 
Sector Academic/University 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation Royal Netherlands Academy of Arts and Sciences
Department Hubrecht Institute
Country Netherlands 
Sector Academic/University 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation University of Copenhagen
Country Denmark 
Sector Academic/University 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation University of Groningen
Country Netherlands 
Sector Academic/University 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation University of Kyoto
Country Japan 
Sector Academic/University 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description Euratrans 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin Smith is a PI on this collaboration.
Collaborator Contribution European large-scale functional genomics in the rat for translational research
Impact http://www.euratrans.eu/
Start Year 2010
 
Description EuroStemCell 
Organisation Centre for Genomic Regulation (CRG)
Country Spain 
Sector Academic/University 
PI Contribution Austin is a principal investigator for this collaboration
Collaborator Contribution EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh
Impact www.eurostemcell.org
Start Year 2010
 
Description EuroStemCell 
Organisation Dando, Weiss & Colucci Ltd
Country United Kingdom 
Sector Private 
PI Contribution Austin is a principal investigator for this collaboration
Collaborator Contribution EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh
Impact www.eurostemcell.org
Start Year 2010
 
Description EuroStemCell 
Organisation JDRF Center for Beta Cell Therapy in Diabetes
Country Belgium 
Sector Academic/University 
PI Contribution Austin is a principal investigator for this collaboration
Collaborator Contribution EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh
Impact www.eurostemcell.org
Start Year 2010
 
Description EuroStemCell 
Organisation Life and Brain GmbH
Country Germany 
Sector Private 
PI Contribution Austin is a principal investigator for this collaboration
Collaborator Contribution EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh
Impact www.eurostemcell.org
Start Year 2010
 
Description EuroStemCell 
Organisation Lund University
Country Sweden 
Sector Academic/University 
PI Contribution Austin is a principal investigator for this collaboration
Collaborator Contribution EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh
Impact www.eurostemcell.org
Start Year 2010
 
Description EuroStemCell 
Organisation National Institute of Health and Medical Research (INSERM)
Country France 
Sector Public 
PI Contribution Austin is a principal investigator for this collaboration
Collaborator Contribution EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh
Impact www.eurostemcell.org
Start Year 2010
 
Description EuroStemCell 
Organisation National University of Ireland, Galway
Country Ireland 
Sector Academic/University 
PI Contribution Austin is a principal investigator for this collaboration
Collaborator Contribution EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh
Impact www.eurostemcell.org
Start Year 2010
 
Description EuroStemCell 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin is a principal investigator for this collaboration
Collaborator Contribution EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh
Impact www.eurostemcell.org
Start Year 2010
 
Description EuroStemCell 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin is a principal investigator for this collaboration
Collaborator Contribution EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh
Impact www.eurostemcell.org
Start Year 2010
 
Description EuroStemCell 
Organisation University of Milan
Country Italy 
Sector Academic/University 
PI Contribution Austin is a principal investigator for this collaboration
Collaborator Contribution EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh
Impact www.eurostemcell.org
Start Year 2010
 
Description EuroStemCell 
Organisation University of Sheffield
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin is a principal investigator for this collaboration
Collaborator Contribution EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. It is a partnership of scientists, clinicians, ethicists, social scientists and science communicators. It is coordinated by the University of Edinburgh
Impact www.eurostemcell.org
Start Year 2010
 
Description EuroSyStem 
Organisation Austrian Academy of Sciences
Department Institute of Molecular Biotechnology
Country Austria 
Sector Academic/University 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation European Institute of Oncology (IEO)
Country Italy 
Sector Charity/Non Profit 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation German Cancer Research Center
Country Germany 
Sector Public 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation Helmholtz Association of German Research Centres
Department Helmholtz Zentrum Munchen
Country Germany 
Sector Public 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation Institute of Genetics and Molecular and Cellular Biology (IGBMC)
Country France 
Sector Academic/University 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation Lund University
Country Sweden 
Sector Academic/University 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation Netherlands Cancer Institute (NKI)
Country Netherlands 
Sector Academic/University 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation Oxford Gene Technology
Country United Kingdom 
Sector Private 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation Pasteur Institute, Paris
Country France 
Sector Academic/University 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation Royal Netherlands Academy of Arts and Sciences
Department Hubrecht Institute
Country Netherlands 
Sector Academic/University 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation San Raffaele Hospital
Department San Raffaele Scientific Institute (SRSI)
Country Italy 
Sector Academic/University 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation Swiss Federal Institute of Technology in Lausanne (EPFL)
Country Switzerland 
Sector Public 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation Technical University of Dresden
Country Germany 
Sector Academic/University 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation University Medical Center Gronigen
Country Netherlands 
Sector Hospitals 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation University of Leipzig
Department Ingo Roeder Institute for Medical Informatics
Country Germany 
Sector Academic/University 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation University of Milan
Country Italy 
Sector Academic/University 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description EuroSyStem 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution PI and Scientific Coordinator
Collaborator Contribution 4 PIs2 PIs 2 PIs 1 PI1 PI2 PIs 1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI1 PI2 PIs 1 PI1 PI3 PIs
Impact see website http://www.eurosystemproject.eu
Start Year 2007
 
Description FP7 Project Pluripotent Stem Cell resources for mesodermal medicine (PluriMes) 
Organisation European Research Centre for Biology and Medicine (Centre Européen de Recherche en Biologie et en Médecine)
Country France 
Sector Academic/University 
PI Contribution Austin Smith is responsible for overall scientific coordination of the project and leads work package 1, translating current advances and understanding of rodent pluripotency to develop and refine conditions that promote homogeneous naïve state for human pluripotent stem cells.
Collaborator Contribution By interlinking complementary biological and computational expertise, the partners aim to drive the generation of new knowledge on the characteristics of normal and abnormal stem cells. By harnessing the capacity of pluripotent stem cells to produce functional cell types with precision and at scale, researchers hope to enable new treatment modalities for degenerative diseases. The PluriMes project is specifically targeted at therapies for muscle, bone and cartilage.
Impact DOI: http://dx.doi.org/10.1016/j.cell.2014.08.029 DOI:10.1038/nprot.2014.102
Start Year 2014
 
Description FP7 Project Pluripotent Stem Cell resources for mesodermal medicine (PluriMes) 
Organisation Leiden University Medical Center
Country Netherlands 
Sector Multiple 
PI Contribution Austin Smith is responsible for overall scientific coordination of the project and leads work package 1, translating current advances and understanding of rodent pluripotency to develop and refine conditions that promote homogeneous naïve state for human pluripotent stem cells.
Collaborator Contribution By interlinking complementary biological and computational expertise, the partners aim to drive the generation of new knowledge on the characteristics of normal and abnormal stem cells. By harnessing the capacity of pluripotent stem cells to produce functional cell types with precision and at scale, researchers hope to enable new treatment modalities for degenerative diseases. The PluriMes project is specifically targeted at therapies for muscle, bone and cartilage.
Impact DOI: http://dx.doi.org/10.1016/j.cell.2014.08.029 DOI:10.1038/nprot.2014.102
Start Year 2014
 
Description FP7 Project Pluripotent Stem Cell resources for mesodermal medicine (PluriMes) 
Organisation Pluriomics BV
Country Netherlands 
Sector Private 
PI Contribution Austin Smith is responsible for overall scientific coordination of the project and leads work package 1, translating current advances and understanding of rodent pluripotency to develop and refine conditions that promote homogeneous naïve state for human pluripotent stem cells.
Collaborator Contribution By interlinking complementary biological and computational expertise, the partners aim to drive the generation of new knowledge on the characteristics of normal and abnormal stem cells. By harnessing the capacity of pluripotent stem cells to produce functional cell types with precision and at scale, researchers hope to enable new treatment modalities for degenerative diseases. The PluriMes project is specifically targeted at therapies for muscle, bone and cartilage.
Impact DOI: http://dx.doi.org/10.1016/j.cell.2014.08.029 DOI:10.1038/nprot.2014.102
Start Year 2014
 
Description FP7 Project Pluripotent Stem Cell resources for mesodermal medicine (PluriMes) 
Organisation Sapienza University of Rome
Country Italy 
Sector Academic/University 
PI Contribution Austin Smith is responsible for overall scientific coordination of the project and leads work package 1, translating current advances and understanding of rodent pluripotency to develop and refine conditions that promote homogeneous naïve state for human pluripotent stem cells.
Collaborator Contribution By interlinking complementary biological and computational expertise, the partners aim to drive the generation of new knowledge on the characteristics of normal and abnormal stem cells. By harnessing the capacity of pluripotent stem cells to produce functional cell types with precision and at scale, researchers hope to enable new treatment modalities for degenerative diseases. The PluriMes project is specifically targeted at therapies for muscle, bone and cartilage.
Impact DOI: http://dx.doi.org/10.1016/j.cell.2014.08.029 DOI:10.1038/nprot.2014.102
Start Year 2014
 
Description FP7 Project Pluripotent Stem Cell resources for mesodermal medicine (PluriMes) 
Organisation Stem Cell Technologies
Country Canada 
Sector Private 
PI Contribution Austin Smith is responsible for overall scientific coordination of the project and leads work package 1, translating current advances and understanding of rodent pluripotency to develop and refine conditions that promote homogeneous naïve state for human pluripotent stem cells.
Collaborator Contribution By interlinking complementary biological and computational expertise, the partners aim to drive the generation of new knowledge on the characteristics of normal and abnormal stem cells. By harnessing the capacity of pluripotent stem cells to produce functional cell types with precision and at scale, researchers hope to enable new treatment modalities for degenerative diseases. The PluriMes project is specifically targeted at therapies for muscle, bone and cartilage.
Impact DOI: http://dx.doi.org/10.1016/j.cell.2014.08.029 DOI:10.1038/nprot.2014.102
Start Year 2014
 
Description FP7 Project Pluripotent Stem Cell resources for mesodermal medicine (PluriMes) 
Organisation Swiss Federal Institute of Technology in Lausanne (EPFL)
Country Switzerland 
Sector Public 
PI Contribution Austin Smith is responsible for overall scientific coordination of the project and leads work package 1, translating current advances and understanding of rodent pluripotency to develop and refine conditions that promote homogeneous naïve state for human pluripotent stem cells.
Collaborator Contribution By interlinking complementary biological and computational expertise, the partners aim to drive the generation of new knowledge on the characteristics of normal and abnormal stem cells. By harnessing the capacity of pluripotent stem cells to produce functional cell types with precision and at scale, researchers hope to enable new treatment modalities for degenerative diseases. The PluriMes project is specifically targeted at therapies for muscle, bone and cartilage.
Impact DOI: http://dx.doi.org/10.1016/j.cell.2014.08.029 DOI:10.1038/nprot.2014.102
Start Year 2014
 
Description FP7 Project Pluripotent Stem Cell resources for mesodermal medicine (PluriMes) 
Organisation Technical University of Dresden
Country Germany 
Sector Academic/University 
PI Contribution Austin Smith is responsible for overall scientific coordination of the project and leads work package 1, translating current advances and understanding of rodent pluripotency to develop and refine conditions that promote homogeneous naïve state for human pluripotent stem cells.
Collaborator Contribution By interlinking complementary biological and computational expertise, the partners aim to drive the generation of new knowledge on the characteristics of normal and abnormal stem cells. By harnessing the capacity of pluripotent stem cells to produce functional cell types with precision and at scale, researchers hope to enable new treatment modalities for degenerative diseases. The PluriMes project is specifically targeted at therapies for muscle, bone and cartilage.
Impact DOI: http://dx.doi.org/10.1016/j.cell.2014.08.029 DOI:10.1038/nprot.2014.102
Start Year 2014
 
Description FP7 Project Pluripotent Stem Cell resources for mesodermal medicine (PluriMes) 
Organisation University College London
Department Division of Biosciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin Smith is responsible for overall scientific coordination of the project and leads work package 1, translating current advances and understanding of rodent pluripotency to develop and refine conditions that promote homogeneous naïve state for human pluripotent stem cells.
Collaborator Contribution By interlinking complementary biological and computational expertise, the partners aim to drive the generation of new knowledge on the characteristics of normal and abnormal stem cells. By harnessing the capacity of pluripotent stem cells to produce functional cell types with precision and at scale, researchers hope to enable new treatment modalities for degenerative diseases. The PluriMes project is specifically targeted at therapies for muscle, bone and cartilage.
Impact DOI: http://dx.doi.org/10.1016/j.cell.2014.08.029 DOI:10.1038/nprot.2014.102
Start Year 2014
 
Description FP7 Project Pluripotent Stem Cell resources for mesodermal medicine (PluriMes) 
Organisation University of Sheffield
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin Smith is responsible for overall scientific coordination of the project and leads work package 1, translating current advances and understanding of rodent pluripotency to develop and refine conditions that promote homogeneous naïve state for human pluripotent stem cells.
Collaborator Contribution By interlinking complementary biological and computational expertise, the partners aim to drive the generation of new knowledge on the characteristics of normal and abnormal stem cells. By harnessing the capacity of pluripotent stem cells to produce functional cell types with precision and at scale, researchers hope to enable new treatment modalities for degenerative diseases. The PluriMes project is specifically targeted at therapies for muscle, bone and cartilage.
Impact DOI: http://dx.doi.org/10.1016/j.cell.2014.08.029 DOI:10.1038/nprot.2014.102
Start Year 2014
 
Description Gene Targeting/ Univ of Edinburgh/ SCI 
Organisation University of Edinburgh
Department The Roslin Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution Gene targeting by homologous recombination in the rat
Collaborator Contribution Gene targeting by homologous recombination in the rat
Impact n./a
Start Year 2010
 
Description George Vassiliou - David Bates 
Organisation University of Nottingham
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: George Vassiliou - academic collaboration
Collaborator Contribution Collaboration with David Bates - academic collaboration.
Impact Academic collaboration
Start Year 2017
 
Description George Vassiliou - Gaslini Children's Hospital 
Organisation Gaslini Children's Hospital
Country Italy 
Sector Hospitals 
PI Contribution CSCI PI: George Vassiliou; Collaborative research.
Collaborator Contribution Collaboration with Francesco Frassoni; Collaborative research.
Impact Collaborative research.
Start Year 2016
 
Description George Vassiliou - John Dick 
Organisation University of Toronto
Country Canada 
Sector Academic/University 
PI Contribution CSCI PI: George Vassiliou - academic collaboration.
Collaborator Contribution Collaboration with John Dick - academic collaboration.
Impact Academic collaboration.
Start Year 2017
 
Description George Vassiliou - Kymab Ltd 
Organisation Kymab
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI: George Vassiliou; Commercial collaboration.
Collaborator Contribution Commercial collaboration.
Impact Commercial collaboration.
Start Year 2016
 
Description George Vassiliou - Liran Shlush 
Organisation Weizmann Institute of Science
Country Israel 
Sector Academic/University 
PI Contribution CSCI PI: George Vassiliou - academic collaboration.
Collaborator Contribution Collaboration with Liran Shlush - academic collaboration.
Impact Academic collaboration.
Start Year 2017
 
Description George Vassiliou - Memorial Sloane Kettering Cancer Center 
Organisation Memorial Sloan Kettering Cancer Center
Country United States 
Sector Academic/University 
PI Contribution CSCI PI: George Vassiliou; Collaborative research.
Collaborator Contribution Collaboration with Scott Armstrong; Collaborative research.
Impact Collaborative research.
Start Year 2016
 
Description George Vassiliou - Sanger 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution CSCI PI: George Vassiliou; Collaborative research.
Collaborator Contribution Collaboration with Ele Zeggini, Kosuke Yusa, Paul Kellam; Collaborative research.
Impact Collaborative research.
Start Year 2016
 
Description George Vassiliou - Tony Kouzarides 
Organisation University of Cambridge
Department Gurdon Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: George Vassiliou - academic collaboration.
Collaborator Contribution Collaboration with Tony Kouzarides - academic collaboration.
Impact Academic collaboration.
Start Year 2017
 
Description JPA/ CSCR 
Organisation RIKEN
Department RIKEN Center for Developmental Biology
Country Japan 
Sector Public 
PI Contribution Metanalysis of transcriptional circuitries and simulation of robustness, flexibility and dynamic heterogeneity
Collaborator Contribution Metanalysis of transcriptional circuitries and simulation of robustness, flexibility and dynamic heterogeneity
Impact n/a
Start Year 2010
 
Description Jenny Nichols - Keio University 
Organisation Keio University
Country Japan 
Sector Academic/University 
PI Contribution CSCI PI: Jenny Nichols; Pluripotency in the marmoset.
Collaborator Contribution Collaboration with Erika Sasaki; Pluripotency in the marmoset.
Impact Pluripotency in the marmoset.
Start Year 2013
 
Description Jenny Nichols - Memorial Sloane Kettering Cancer Center 
Organisation Memorial Sloan Kettering Cancer Center
Country United States 
Sector Academic/University 
PI Contribution CSCI PI: Jenny Nichols; Publication: Le Bin et al., 2014; Early embryonic lineage decision.
Collaborator Contribution Collaboration with Anna Katerina Hadjantonakis; Publication: Le Bin et al., 2014; Early embryonic lineage decision.
Impact Publication: Le Bin et al., 2014; Early embryonic lineage decision.
Start Year 2013
 
Description Jenny Nichols - University of Bath 
Organisation University of Bath
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Jenny Nichols; Publication: Le Bin et al., 2014; Gene regulatory networks in pluripotent lineages in vivo.
Collaborator Contribution Collaboration with Silvia Munoz-Descalzo; Publication: Le Bin et al., 2014; Gene regulatory networks in pluripotent lineages in vivo.
Impact Publication: Le Bin et al., 2014; Gene regulatory networks in pluripotent lineages in vivo.
Start Year 2013
 
Description Jenny Nichols - University of Copenhagen 
Organisation University of Copenhagen
Department Danish Stem Cell Center (DanStem)
Country Denmark 
Sector Academic/University 
PI Contribution CSCI PI: Jenny Nichols; Publication: Frankenberg et al., 2014; Morgani et al., 2013.
Collaborator Contribution Collaboration with Joshua Brickman; Publication: Frankenberg et al., 2014; Morgani et al., 2013.
Impact Publication: Frankenberg et al., 2014; Morgani et al., 2013.
Start Year 2009
 
Description Jenny Nichols - University of Manchester 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Jenny Nichols; Publication: Grabarek et al., 2012.
Collaborator Contribution Collaboration with Berenika Plusa; Publication: Grabarek et al., 2012.
Impact Publication: Grabarek et al., 2012.
Start Year 2010
 
Description Joo Hyeon-Lee - Walid Khaled 
Organisation University of Cambridge
Department Department of Pharmacology
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Joo-Hyeon Lee - Lee lab collaborates with Khaled's group to characterise novel oncogene utilising mouse lung organoid system established in Lee Lab. This work is currently under revision in Nat Com.
Collaborator Contribution Collaboration with Walid Khaled - Lee lab collaborates with Khaled's group to characterise novel oncogene utilising mouse lung organoid system established in Lee Lab. This work is currently under revision in Nat Com.
Impact Lee lab collaborates with Khaled's group to characterise novel oncogene utilising mouse lung organoid system established in Lee Lab. This work is currently under revision in Nat Com.
Start Year 2017
 
Description Joo-Hyeon Lee - CIMR 
Organisation University of Cambridge
Department Cambridge Institute for Medical Research (CIMR)
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Joo-Hyeon Lee; Dr Tammela and myself have been focusing on developing lung cancer models using lung organoid systems.
Collaborator Contribution Collaboration with Tuomas Tammela; Dr Tammela and myself have been focusing on developing lung cancer models using lung organoid systems.
Impact Dr Tammela and myself have been focusing on developing lung cancer models using lung organoid systems.
Start Year 2014
 
Description Joo-Hyeon Lee - CIMR (Marciniak) 
Organisation University of Cambridge
Department Cambridge Institute for Medical Research (CIMR)
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Joo-Hyeon Lee; Lee lab shares our expertise in developing alveolar organoid system, which will be used in establishing a disease model of idiopathic pulmonary fibrosis (IPF) by genetic mutation of Sftpc in Marciniak's group.
Collaborator Contribution Collaboration with Stefan Marciniak; Lee lab shares our expertise in developing alveolar organoid system, which will be used in establishing a disease model of idiopathic pulmonary fibrosis (IPF) by genetic mutation of Sftpc in Marciniak's group.
Impact Lee lab shares our expertise in developing alveolar organoid system, which will be used in establishing a disease model of idiopathic pulmonary fibrosis (IPF) by genetic mutation of Sftpc in Marciniak's group.
Start Year 2016
 
Description Joo-Hyeon Lee - Dae-Sik Lim 
Organisation Korea Advanced Institute of Science and Technology (KAIST)
Country Korea, Republic of 
Sector Academic/University 
PI Contribution CSCI PI: Joo-Hyeon Lee - Lee co-supervises Hae-Yon Jeon who is a postdoc in Lim's lab to understand the functional role of Hippo signalling in lung development and regeneration.
Collaborator Contribution Collaboration with Dae-Sik Lim - Lee co-supervises Hae-Yon Jeon who is a postdoc in Lim's lab to understand the functional role of Hippo signalling in lung development and regeneration.
Impact Lee co-supervises Hae-Yon Jeon who is a postdoc in Lim's lab to understand the functional role of Hippo signalling in lung development and regeneration.
Start Year 2017
 
Description Joo-Hyeon Lee - Mick Fellow 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI: Joo-Hyeon Lee - Dr Mick co-supervises Kelly Evans who is a PhD student in Lee Lab to establish human lung organoids for use of drug toxicity and CRISPR screening.
Collaborator Contribution Collaboration with Mick Fellow - Dr Mick co-supervises Kelly Evans who is a PhD student in Lee Lab to establish human lung organoids for use of drug toxicity and CRISPR screening.
Impact Dr Mick co-supervises Kelly Evans who is a PhD student in Lee Lab to establish human lung organoids for use of drug toxicity and CRISPR screening.
Start Year 2017
 
Description Joo-Hyeon Lee - Papworth Hospital 
Organisation Papworth Hospital NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution CSCI PI:: Joo-Hyeon Lee; Lee's group focuses on developing alveolar organoids derived from IPF patient samples. In particular, with Dr Parfrey, we try to understand the crosstalk between epithelial cells, endothelial cells, and fibroblasts in pathogenesis of IPF.
Collaborator Contribution Collaboration with Helen Parfrey; Lee's group focuses on developing alveolar organoids derived from IPF patient samples. In particular, with Dr Parfrey, we try to understand the crosstalk between epithelial cells, endothelial cells, and fibroblasts in pathogenesis of IPF.
Impact Lee's group focuses on developing alveolar organoids derived from IPF patient samples. In particular, with Dr Parfrey, we try to understand the crosstalk between epithelial cells, endothelial cells, and fibroblasts in pathogenesis of IPF.
Start Year 2016
 
Description Joo-Hyeon Lee - Sam Janes 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Joo-Hyeon Lee - Lee lab shares our expertise in developing human lung organoid system, which will be used in establishing a modelling human lung cancer with Janes' group.
Collaborator Contribution Collaboration with Sam Janes - Lee lab shares our expertise in developing human lung organoid system, which will be used in establishing a modelling human lung cancer with Janes' group.
Impact Lee lab shares our expertise in developing human lung organoid system, which will be used in establishing a modelling human lung cancer with Janes' group.
Start Year 2017
 
Description Joo-Hyeon Lee - University of Cambridge (Enginnering) 
Organisation University of Cambridge
Department MRC Biostatistics Unit
Country United Kingdom 
Sector Public 
PI Contribution CSCI PI: Joo-Hyeon Lee; Huang's group has an expertise in developing biomimetic organ-on-chips for high throughput drug screening. Lee's group is closely collaborating with Dr Huang to recapitulate the microenviroments including a vessel formation for our lung organoids.
Collaborator Contribution Collaboration with Yan Yan Shery Huang; Huang's group has an expertise in developing biomimetic organ-on-chips for high throughput drug screening. Lee's group is closely collaborating with Dr Huang to recapitulate the microenviroments including a vessel formation for our lung organoids.
Impact Huang's group has an expertise in developing biomimetic organ-on-chips for high throughput drug screening. Lee's group is closely collaborating with Dr Huang to recapitulate the microenviroments including a vessel formation for our lung organoids.
Start Year 2016
 
Description Joo-Hyeon Lee - Wilhelm Palm and Tuomas Tammela 
Organisation Memorial Sloan Kettering Cancer Center
Country United States 
Sector Academic/University 
PI Contribution CSCI PI: Joo-Hyeon Lee - Lee lab shares our expertise in developing lung tumouroids to understand "Metabolic heterogeneity in K-Ras-driven lung cancer" with Palm's lab, Papagiannakoupolos's lab and Tammela's lab. We awarded the Hope Funds Collaborative Competition Award for this collaboration.
Collaborator Contribution Collaboration with Wilhem Palm and Tuomas Tammela - Lee lab shares our expertise in developing lung tumouroids to understand "Metabolic heterogeneity in K-Ras-driven lung cancer" with Palm's lab, Papagiannakoupolos's lab and Tammela's lab. We awarded the Hope Funds Collaborative Competition Award for this collaboration.
Impact Lee lab shares our expertise in developing lung tumouroids to understand "Metabolic heterogeneity in K-Ras-driven lung cancer" with Palm's lab, Papagiannakoupolos's lab and Tammela's lab. We awarded the Hope Funds Collaborative Competition Award for this collaboration.
Start Year 2017
 
Description Jose Silva - Black Family Stem Cell Institute 
Organisation Mount Sinai Hospital (USA)
Department Black Family Stem Cell Institute
Country United States 
Sector Hospitals 
PI Contribution CSCI PI: Jose Silva; Ongoing collaborative work resulting in multiple publications.
Collaborator Contribution Collaboration with Jianlong Wang; Ongoing collaborative work resulting in multiple publications.
Impact Ongoing collaborative work resulting in multiple publications.
Start Year 2011
 
Description Kevin Chalut - University of Cambridge (Biochemistry) 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Kevin Chalut; Developing cell encapsulating devices for use with stem cell systems.
Collaborator Contribution Collaboration with Florian Hollfelder; Developing cell encapsulating devices for use with stem cell systems.
Impact Developing cell encapsulating devices for use with stem cell systems.
Start Year 2014
 
Description Kevin Chalut - University of Cambridge (Physics) 
Organisation University of Cambridge
Department Faculty of Philosophy
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Kevin Chalut; Developed microfluidics for stem cell analysis, recent Nature Materials, coI on submitted BBSRC research grant
Collaborator Contribution Collaboration with Ulrich Keyser; Developed microfluidics for stem cell analysis, recent Nature Materials, coI on submitted BBSRC research grant
Impact Developed microfluidics for stem cell analysis, recent Nature Materials, coI on submitted BBSRC research grant.
Start Year 2012
 
Description Kevin Chalut - University of Exeter 
Organisation University of Exeter
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Kevin Chalut; Developed microfluidics for stem cell analysis, recent paper in Nature Materials.
Collaborator Contribution Collaboration with Stefano Pagliara; Developed microfluidics for stem cell analysis, recent paper in Nature Materials
Impact Developed microfluidics for stem cell analysis, recent paper in Nature Materials.
Start Year 2011
 
Description Kevin Chalut - University of Manchester 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Kevin Chalut; Physical biology of early embryogenesis; collaboration on Leverhulme Trust research grant.
Collaborator Contribution Collaboration with Berenika Plusa; Physical biology of early embryogenesis; collaboration on Leverhulme Trust research grant.
Impact Physical biology of early embryogenesis; collaboration on Leverhulme Trust research grant.
Start Year 2013
 
Description Ludovic Vallier - AstraZeneca 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI: Ludovic Vallier; Modeling diabetes in vitro using hIPSCs.
Collaborator Contribution Collaboration with Barry Rosen; Modeling diabetes in vitro using hIPSCs.
Impact Modeling diabetes in vitro using hIPSCs.
Start Year 2015
 
Description Ludovic Vallier - Boston University 
Organisation Boston University
Country United States 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration; 1 publication.
Collaborator Contribution Collaboration with Darrell Kotton; Scientific collaboration; 1 publication.
Impact Scientific collaboration; 1 publication.
Start Year 2013
 
Description Ludovic Vallier - CN Bio Innovations Ltd TransTissue Technologies 
Organisation CN Bio Innovations Ltd
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI: Ludovic Vallier; Developing 3D system for modeling liver disease.
Collaborator Contribution Collaboration with David Hughes; Developing 3D system for modeling liver disease.
Impact Developing 3D system for modeling liver disease.
Start Year 2010
 
Description Ludovic Vallier - DefiniGEN 
Organisation DefiniGEN
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI: Ludovic Vallier; Founder and CSO.
Collaborator Contribution Collaboration with Marcus Yeo; CEO
Impact DefiniGEN.
Start Year 2012
 
Description Ludovic Vallier - Giuseppe Mazza 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier - collaborative project, grants and publications.
Collaborator Contribution Collaboration with Giuseppe Mazza - collaborative project, grants and publications.
Impact Collaborative project, grants and publications.
Start Year 2017
 
Description Ludovic Vallier - Imperial College London 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration; 2 publications.
Collaborator Contribution Collaboration with Jorge Ferrer; Scientific collaboration; 2 publications.
Impact Scientific collaboration; 2 publications.
Start Year 2010
 
Description Ludovic Vallier - Institute of Medical Biology, Singapore 
Organisation Agency for Science, Technology and Research (A*STAR)
Department Institute of Medical Biology
Country Singapore 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration; publications.
Collaborator Contribution Collaboration with Ray Dunn; Scientific collaboration; publications.
Impact Scientific collaboration; publications.
Start Year 2009
 
Description Ludovic Vallier - Jake Liang 
Organisation National Institutes of Health (NIH)
Country United States 
Sector Public 
PI Contribution CSCI PI: Ludovic Valllier - collaborative project, publications.
Collaborator Contribution Collaboration with Jake Liang - collaborative project, publications.
Impact Collaborative project, publications.
Start Year 2017
 
Description Ludovic Vallier - Jernej Urle and Kathy Niakkan 
Organisation Francis Crick Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution CSCI PI: Ludovic Vallier - collaborative project, publications.
Collaborator Contribution Collaboration with Jernej Urle and Kathy Niakan.
Impact Collaborative project, publications.
Start Year 2017
 
Description Ludovic Vallier - Kim Jensen 
Organisation University of Copenhagen
Department Biotech Research and Innovation Center (BRIC)
Country Denmark 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier - Collaborative project, publication.
Collaborator Contribution Collaboration with Kim B Jensen - Collaborative project, publication.
Impact Collaborative project, publication.
Start Year 2017
 
Description Ludovic Vallier - NIH 
Organisation National Institutes of Health (NIH)
Country United States 
Sector Public 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration; Publications and grant.
Collaborator Contribution Collaboration with Tom Wynn; Scientific collaboration; Publications and grant.
Impact Scientific collaboration; Publications and grant.
Start Year 2011
 
Description Ludovic Vallier - Sanger 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration; 1 publication.
Collaborator Contribution Collaboration with David Gaffney.; Scientific collaboration; 1 publication.
Impact Scientific collaboration; 1 publication.
Start Year 2012
 
Description Ludovic Vallier - Sanger 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration.
Collaborator Contribution Collaboration with Oliver Bilker and Gordon Dougan; Scientific collaboration.
Impact Scientific collaboration.
Start Year 2012
 
Description Ludovic Vallier - Sarah Teichmann 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution CSCI PI: Ludovic Vallier - collaborative project, publications.
Collaborator Contribution Collaboration with Sarah Teichman - collaborative project, publications.
Impact Collaborative project, publications.
Start Year 2017
 
Description Ludovic Vallier - StemCell Technologies 
Organisation Stemcell Technologies
Country Canada 
Sector Private 
PI Contribution CSCI PI: Ludovic Vallier; Development of culture conditions to differentiate hPSCs into gut organoid.
Collaborator Contribution Collaboration with Michael Riedel; Development of culture conditions to differentiate hPSCs into gut organoid
Impact Development of culture conditions to differentiate hPSCs into gut organoid
Start Year 2015
 
Description Ludovic Vallier - Tokyo electron 
Organisation Tokyo Electron
Country Japan 
Sector Private 
PI Contribution CSCI PI: Ludovic Vallier; Development of large scale system for derivation and differentiation of hIPSCs.
Collaborator Contribution Collaboration with Daizo Kurishita; Development of large scale system for derivation and differentiation of hIPSCs.
Impact Development of large scale system for derivation and differentiation of hIPSCs.
Start Year 2012
 
Description Ludovic Vallier - Uiversity of Cambridge (Medicine) 
Organisation University of Cambridge
Department Department of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration; 1 grant application.
Collaborator Contribution Collaboration with Andres Floto; Scientific collaboration; 1 grant application.
Impact Scientific collaboration; 1 grant application.
Start Year 2015
 
Description Ludovic Vallier - University College London 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration; 3 grant applications.
Collaborator Contribution Collaboration with Paolo De Coppi; Scientific collaboration; 3 grant applications.
Impact Scientific collaboration; 3 grant applications.
Start Year 2012
 
Description Ludovic Vallier - University College London 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration; 3 publications.
Collaborator Contribution Collaboration with David Lomas; Scientific collaboration; 3 publications.
Impact Scientific collaboration; 3 publications.
Start Year 2010
 
Description Ludovic Vallier - University of Cambridge (Haematology) 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration.
Collaborator Contribution Collaboration with Cedric Ghevaert and Willem Ouwehand; scientific collaboration.
Impact Scientific collaboration.
Start Year 2012
 
Description Ludovic Vallier - University of Cambridge (Medicine - Lehner) 
Organisation University of Cambridge
Department Department of Biochemistry
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration; 1 publication.
Collaborator Contribution Collaboration with Paul Lehner; Scientific collaboration; 1 publication.
Impact Scientific collaboration; 1 publication.
Start Year 2015
 
Description Ludovic Vallier - University of Cambridge (Spillantini) 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration.
Collaborator Contribution Collaboration with Maria Grazia Spillantini; Scientific collaboration.
Impact Scientific collaboration.
Start Year 2012
 
Description Ludovic Vallier - University of Cambridge (Surgery/Medicine) 
Organisation University of Cambridge
Department Department of Public Health and Primary Care
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration; grant application.
Collaborator Contribution Collaboration with Kourosh Saeb-Parsy; Scientific collaboration; grant application.
Impact Scientific collaboration; grant application.
Start Year 2013
 
Description Ludovic Vallier - University of Cambridge (Vidal-Puig) 
Organisation University of Cambridge
Department Department of Haematology
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration.
Collaborator Contribution Collaboration with Toni Vidal-Puig; Scientific collaboration.
Impact Scientific collaboration.
Start Year 2015
 
Description Ludovic Vallier - University of Edinburgh 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration; 1 publication and grant application.
Collaborator Contribution Collaboration with Siddharthan Chandran; Scientific collaboration; 1 publication and grant application.
Impact Scientific collaboration; 1 publication and grant application.
 
Description Ludovic Vallier - University of Exeter 
Organisation University of Exeter
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration; 1 publication.
Collaborator Contribution Collaboration with Andrew Hatersley; Scientific collaboration; 1 publication.
Impact Scientific collaboration; 1 publication.
Start Year 2010
 
Description Ludovic Vallier - University of Georgia 
Organisation University of Georgia
Country United States 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration; 1 publication.
Collaborator Contribution Collaboration with Stephen Dalton; Scientific collaboration; 1 publication.
Impact Scientific collaboration; 1 publication.
Start Year 2012
 
Description Ludovic Vallier - University of Manchester 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Ludovic Vallier; Scientific collaboration; 3 publications.
Collaborator Contribution Collaboration with Neil Hanley; Scientific collaboration; 3 publications.
Impact Scientific collaboration; 3 publications.
Start Year 2010
 
Description Maria Alcolea - Alessandro Esposito 
Organisation Medical Research Council (MRC)
Department MRC Cancer Unit
Country United Kingdom 
Sector Public 
PI Contribution CSCI PI: Maria Alcolea. Research collaboration.
Collaborator Contribution Collaboration with Alessandro Esposito; Research Collaboration.
Impact Research collaboration - ongoing.
Start Year 2017
 
Description Maria Alcolea - Antonia Obrador 
Organisation Hospital Son Espases
Country Spain 
Sector Hospitals 
PI Contribution CSCI PI: Maria Alcolea. Research collaboration
Collaborator Contribution Collaboration with Antonia Obrador; Research collaboration
Impact Research collaboration - ongoing
Start Year 2017
 
Description Maria Alcolea - Ben Simons 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Maria Alcolea. PhD student and postdoc co-supervision; MRC research grant collaboration.
Collaborator Contribution Collaboration with Ben Simons; PhD student and postdoc co-supervision; MRC research grant collaboration.
Impact PhD student and postdoc co-supervision; MRC research grant collaboration.
Start Year 2016
 
Description Maria Alcolea - Daniel Munoz-Espin 
Organisation University of Cambridge
Department Department of Oncology
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Maria Alcolea. Research collaboration.
Collaborator Contribution Collaboration with Daniel Munoz-Espin; Research collaboration
Impact Research collaboration - ongoing
Start Year 2017
 
Description Maria Alcolea - George Gordon/ Sarah Bondiek 
Organisation Cancer Research UK Cambridge Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Maria Alcolea; Research collaboration
Collaborator Contribution Collaboration with George Gordon/ Sarah Bondiek; Research collaboration
Impact Research collaboration
Start Year 2016
 
Description Maria Alcolea - Julio Saez-Rodriguez 
Organisation EMBL European Bioinformatics Institute (EMBL - EBI)
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Maria Alcolea. Research collaboration.
Collaborator Contribution Collaboration with Julio Saez-Rodriguez; Research collaboration.
Impact Research collaboration - ongoing.
Start Year 2017
 
Description Methylation analyses 
Organisation Babraham Institute
Country United Kingdom 
Sector Private 
PI Contribution Methylation analyses
Collaborator Contribution Methylation analyses
Impact n/a
Start Year 2011
 
Description NeuroStemCell 
Organisation Babraham Institute
Department Stem Cell Sciences UK Ltd
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells.
Collaborator Contribution European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models.
Impact http://www.neurostemcell.org/
Start Year 2008
 
Description NeuroStemCell 
Organisation Cardiff University
Department School of Biosciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells.
Collaborator Contribution European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models.
Impact http://www.neurostemcell.org/
Start Year 2008
 
Description NeuroStemCell 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells.
Collaborator Contribution European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models.
Impact http://www.neurostemcell.org/
Start Year 2008
 
Description NeuroStemCell 
Organisation Institute of Biomedical Imagery (I2BM)
Country France 
Sector Academic/University 
PI Contribution Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells.
Collaborator Contribution European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models.
Impact http://www.neurostemcell.org/
Start Year 2008
 
Description NeuroStemCell 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells.
Collaborator Contribution European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models.
Impact http://www.neurostemcell.org/
Start Year 2008
 
Description NeuroStemCell 
Organisation Lund University
Country Sweden 
Sector Academic/University 
PI Contribution Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells.
Collaborator Contribution European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models.
Impact http://www.neurostemcell.org/
Start Year 2008
 
Description NeuroStemCell 
Organisation National Institute of Health and Medical Research (INSERM)
Country France 
Sector Public 
PI Contribution Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells.
Collaborator Contribution European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models.
Impact http://www.neurostemcell.org/
Start Year 2008
 
Description NeuroStemCell 
Organisation NsGene A/S
Country Denmark 
Sector Private 
PI Contribution Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells.
Collaborator Contribution European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models.
Impact http://www.neurostemcell.org/
Start Year 2008
 
Description NeuroStemCell 
Organisation Sapio
Department BioRep
Country Italy 
Sector Private 
PI Contribution Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells.
Collaborator Contribution European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models.
Impact http://www.neurostemcell.org/
Start Year 2008
 
Description NeuroStemCell 
Organisation University of Bonn
Country Germany 
Sector Academic/University 
PI Contribution Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells.
Collaborator Contribution European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models.
Impact http://www.neurostemcell.org/
Start Year 2008
 
Description NeuroStemCell 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells.
Collaborator Contribution European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models.
Impact http://www.neurostemcell.org/
Start Year 2008
 
Description NeuroStemCell 
Organisation University of Milan
Country Italy 
Sector Academic/University 
PI Contribution Austin Smith is a Principal Investigator on this collaboration. Austin will contribute extensively to WP1 and 2 and play a role in stability studies in WP5. The group will provide to the consortium recently derived rat ES cells and rat NS cells, in addition to human NS cells.
Collaborator Contribution European Consortium for Stem Cell Therapy in Neurodegenerative Diseases. NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world-leading consortium that can develop stem cell based therapies for Parkinson´s disease and Huntington´s disease toward clinical application. NeuroStemcell is focused on the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesencephalic dopaminergic and striatal GABAergic neuronal differentiation, generated either directly from human embryonic stem (ES) cells, from induced Pluripotent Stem (iPS) cells, or from neural stem cells derived from either ES cells, iPS cells or fetal brain, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animal models.
Impact http://www.neurostemcell.org/
Start Year 2008
 
Description Robin Franklin - Domainex 
Organisation Domainex
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI: Robin Franklin; Drug development.
Collaborator Contribution Collaboration with George Buckley; Drug development
Impact Drug development.
Start Year 2016
 
Description Robin Franklin - GSK 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution CSCI PI: Robin Franklin; Case Studentship.
Collaborator Contribution Collaboration with Gareth Wayne; Case Studentship.
Impact Case Studentship.
Start Year 2014
 
Description Robin Franklin - INSERM 
Organisation National Institute of Health and Medical Research (INSERM)
Country France 
Sector Public 
PI Contribution CSCI PI: Robin Franklin; Single publication.
Collaborator Contribution Collaboration with Catherine Lubetzki; Single publication.
Impact Single publication.
Start Year 2010
 
Description Robin Franklin - Lynette Foo 
Organisation Roche Pharmaceuticals
Country Global 
Sector Private 
PI Contribution CSCI PI: Robin Franklin; Joint grant.
Collaborator Contribution Collaboration with Lynette Foo - joint grant
Impact Joint grant.
Start Year 2017
 
Description Robin Franklin - MedImmune 
Organisation MedImmune
Department MedImmune Cambridge
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI: Robin Franklin; Project grant and Studentship.
Collaborator Contribution Collaboration with Clare Jones; Project grant and Studentship.
Impact Project grant and Studentship.
Start Year 2014
 
Description Robin Franklin - Mount Sinai Hospital 
Organisation Mount Sinai Hospital (USA)
Country United States 
Sector Hospitals 
PI Contribution CSCI PI: Robin Franklin; Single publication.
Collaborator Contribution Collaboration with Patrizia Casaccia; Single publication
Impact Single publication.
Start Year 2010
 
Description Robin Franklin - University of California San Francisco 
Organisation University of California, San Francisco
Country United States 
Sector Academic/University 
PI Contribution CSCI PI: Robin Franklin; Joint publications.
Collaborator Contribution Collaboration with Jonah Chan; Joint publications.
Impact Joint publications.
Start Year 2012
 
Description Robin Franklin - University of Cambridge (Clinical Neurosciences) 
Organisation University of Cambridge
Department Department of Genetics
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Robin Franklin; Joint grants and publications.
Collaborator Contribution Collaboration with Mark Kotter. Joint grants and publications.
Impact Joint grants and publications.
 
Description Robin Franklin - University of Edinburgh 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Robin Franklin.
Collaborator Contribution Collaboration with David Lyons.
Impact None yet.
Start Year 2012
 
Description Robin Franklin - University of Edinburgh 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Robin Franklin; Several publications and grants.
Collaborator Contribution Collaboration with Charles ffrench-Constant; Several publications and grants.
Impact Several publications and grants.
 
Description Roger Barker - Cell Therapy Catapult 
Organisation Cell Therapy Catapult
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Roger Barker - Discussion on ES cell trials in PD
Collaborator Contribution Collaboration with Nina Bauer - Discussion on ES cell trials in PD
Impact Discussion on ES cell trials in PD.
Start Year 2015
 
Description Roger Barker - Karolinska Institute 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution SCI PI: Roger Bartker; EU FP7 grant DDPD genes - Defining genes involved in dopamine differentiation and loss in PD
Collaborator Contribution Collaboration with Ernest Arenas - EU FP7 grant DDPD genes - Defining genes involved in dopamine differentiation and loss in PD
Impact EU FP7 grant DDPD genes - Defining genes involved in dopamine differentiation and loss in PD.
Start Year 2011
 
Description Roger Barker - Lund University 
Organisation Lund University
Country Sweden 
Sector Academic/University 
PI Contribution CSCI PI: Roger Barker - Disease modelling with iN cells
Collaborator Contribution Collaboration with Malin Parmar - Disease modelling with iN cells
Impact Disease modelling with iN cells.
Start Year 2011
 
Description Roger Barker - Lund University (Bjorklund) 
Organisation Lund University
Country Sweden 
Sector Academic/University 
PI Contribution CSCI PI: Roger Barker; Neural grafting in PD and disease modelling in PD.
Collaborator Contribution Collaboration with Anders Bjorklund - Neural grafting in PD and disease modelling in PD
Impact Neural grafting in PD and disease modelling in PD.
Start Year 2011
 
Description Roger Barker - MRC Centre for Regenerative Medicine 
Organisation University of Edinburgh
Department MRC Centre for Regenerative Medicine
Country United Kingdom 
Sector Public 
PI Contribution SCI PI: Roger Barker; MRC grant to make GMP grade dopamine cells from hES cells
Collaborator Contribution Collaboration with Tilo Kunath; MRC grant to make GMP grade dopamine cells from hES cells
Impact MRC grant to make GMP grade dopamine cells from hES cells.
Start Year 2012
 
Description Roger Barker - MedImmune 
Organisation MedImmune
Department MedImmune Cambridge
Country United Kingdom 
Sector Private 
PI Contribution CSCI PI: Roger Barker - Project around patient samples and stem cell line from patients
Collaborator Contribution Collaboration with Andy Billington - Project around patient samples and stem cell line from patients
Impact Project around patient samples and stem cell line from patients.
Start Year 2015
 
Description Roger Barker - Pedro R. Cutillas 
Organisation Queen Mary University of London
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Roger Barker; Research collaboration.
Collaborator Contribution Collaboration with Pedro R. Cutillas - research collaboration.
Impact Research collaboration - ongoing
Start Year 2017
 
Description Roger Barker - Pluripotent Stem Cell Plataform (Sheffield) 
Organisation University of Sheffield
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Roger Barker - Genetic/Epigenetic abnormalities in ES derived neurons and induced neurons
Collaborator Contribution Collaboration with Peter Andrews - Genetic/Epigenetic abnormalities in ES derived neurons and induced neurons
Impact Genetic/Epigenetic abnormalities in ES derived neurons and induced neurons.
Start Year 2013
 
Description Roger Barker - Pluripotent Stem Cell Platform (PSCP) 
Organisation Loughborough University
Country United Kingdom 
Sector Academic/University 
PI Contribution CSCI PI: Roger Barker - GMP production of hES cells to dopamine neurons
Collaborator Contribution Collaboration with Mark McCall - GMP production of hES cells to dopamine neurons
Impact GMP production of hES cells to dopamine neurons.
Start Year 2014
 
Description Roger Barker - University of Milan 
Organisation University of Milan
Department Stem Cell Biology and Pharmacology of Neurodegenerative Diseases
Country Italy 
Sector Academic/University 
PI Contribution CSCI PI: Roger Barker; Striatial development in the human and the making of MSNs from hES cells
Collaborator Contribution Collaboration with Elena Cattaneo - Striatial development in the human and the making of MSNs from hES cells
Impact Laboratory of Stem Cell Biology and Pharmacology of Neurodegenerative Diseases.
Start Year 2008
 
Description Sanjay Sinha - Hemoshear Therapeutics 
Organisation Hemoshear Therapeutics
Country United States 
Sector Private 
PI Contribution CSCI PI: Sanjay Sinha; Joint paper submitted.
Collaborator Contribution Collaboration with Brian Wamhoff; Joint paper submitted.
Impact Joint paper submitted.
Start Year 2015
 
Description Sanjay Sinha - INSERM 
Organisation National Institute of Health and Medical Research (INSERM)
Department Inserm Transfert
Country France 
Sector Public 
PI Contribution CSCI PI: Sanjay Sinha; Stroke Association grant.
Collaborator Contribution Collaboration with Anne Joutel; Stroke Association grant.
Impact Stroke Association grant.
Start Year 2015
 
Description Sanjay Sinha - Leiden University Medical Centre 
Organisation Leiden University Medical Center
Country Netherlands 
Sector Multiple 
PI Contribution CSCI PI: Sanjay Sinha; Collaborative research.